



BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

CTN 326: the role of fatty liver in the epidemic of advanced chronic liver disease among people living with HIV: protocol for the LIVEHIV Cohort

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2023-076547
Article Type:	Protocol
Date Submitted by the Author:	09-Jun-2023
Complete List of Authors:	<p>CINQUE, FELICE; McGill University Health Centre, Chronic Viral Illness Service; McGill University Health Centre, Division of Gastroenterology and Hepatology</p> <p>Saeed, Sahar; Queen's University, Public Health Sciences</p> <p>Kablawi, Dana; McGill University Health Centre, Chronic Viral Illness Service; McGill University Health Centre, Division of Gastroenterology and Hepatology</p> <p>Ramos Ballesteros, Luz; McGill University Health Centre, Chronic Viral Illness Service; McGill University Health Centre, Division of Gastroenterology and Hepatology,</p> <p>Elgretli, Wesal; McGill University, Division of Experimental Medicine</p> <p>Moodie, Erica; McGill University, Department of Epidemiology, Biostatistics and Occupational Health</p> <p>Price, Colleen; Canadian HIV/AIDS and Chronic Pain Society</p> <p>Monteith, Ken; COCQ SIDA</p> <p>Cooper, Curtis; Ottawa Hospital Research Institute, Department of Medicine, Division of Infectious Diseases</p> <p>Walmsley, Sharon; University of Toronto, Department of Medicine, Division of Infectious Diseases</p> <p>Pick, Neora; The University of British Columbia</p> <p>Murray, Melanie; The University of British Columbia</p> <p>Kronfli, Nadine; McGill University Health Centre, Chronic Viral Illness Service</p> <p>Costiniuk, Cecilia T.; McGill University, Chronic Viral Illness Service</p> <p>de Pokomandy, Alexandra; McGill University Health Centre, Chronic Viral Illness Service</p> <p>Routy, Jean-Pierre; McGill University Health Centre, Chronic Viral Illness Service</p> <p>Lebouché, Bertrand; McGill University Faculty of Medicine and Health Sciences, Department of Family Medicine; McGill University Health Centre, Chronic Viral Illness Service</p> <p>Klein, Marina; McGill University Health Centre, Chronic Viral Illness Service; McGill University, Department of Epidemiology, Biostatistics and Occupational Health</p> <p>Sebastiani, Giada; McGill University Health Centre, Division of Gastroenterology and Hepatology; McGill University, Division of Experimental Medicine</p>
Keywords:	HIV & AIDS < INFECTIOUS DISEASES, Hepatology < INTERNAL

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	MEDICINE, Quality of Life

SCHOLARONE™
Manuscripts

CTN 326: the role of fatty liver in the epidemic of advanced chronic liver disease among people living with HIV: protocol for the LIVEHIV Cohort

Felice Cinque^{1,2*}, Sahar Saeed^{3*}, Dana Kablawi^{1,2}, Luz Ramos Ballesteros^{1,2}, Wesal Elgretli⁴, Erica E.M. Moodie⁵, Colleen Price⁶, Ken Monteith⁷, Curtis Cooper⁸, Sharon Walmsley⁹, Neora Pick¹⁰, Melanie C.M. Murray¹⁰, Nadine Kronfli², Cecilia Costiniuk², Alexandra De Pokomandy², Jean-Pierre Routy², Bertrand Lebouche^{2,11}, Marina B. Klein^{2,5}, Giada Sebastiani^{1,2,4}

¹Division of Gastroenterology and Hepatology, McGill University Health Centre, Montreal, Canada

²Chronic Viral Illness Service, Division of Infectious Diseases, Department of Medicine, McGill University Health Centre, Montreal, Canada

³Public Health Sciences, Queen's University, Kingston, Canada

⁴Division of Experimental Medicine, McGill University, Montreal, Canada

⁵Department of Epidemiology, Biostatistics and Occupational Health, McGill University

⁶Canadian HIV/AIDS and Chronic Pain Society

⁷COCQ SIDA, Montreal, Canada

⁸Department of Medicine, Division of Infectious Diseases, The Ottawa Hospital, Ottawa Hospital Research Institute, Ottawa, Canada

⁹Department of Medicine, Division of Infectious Diseases, Toronto General Hospital, University of Toronto, Toronto, Canada

¹⁰University of British Columbia, Vancouver, Canada

¹¹Department of Family Medicine, Faculty of Medicine and Health Sciences, McGill University, Montreal, Quebec, Canada

* These authors equally contributed to this work.

Corresponding author’s contact information

Dr Giada Sebastiani, MD
Division of Gastroenterology and Hepatology; Chronic Viral Illness Service
Royal Victoria Hospital, McGill University Health Center
1001 Décarie Blvd.
Montreal, QC H4A 3J1, Canada.
Ph. (514) 843-1616; Fax (514) 843-1421
Email: giada.sebastiani@mcgill.ca

Keywords: HIV; Chronic liver disease, Fatty liver, Antiretroviral therapy, Health-related quality of life

Word count: abstract, 292; manuscript, 3996; Tables, 1; Figures, 2.

ABSTRACT

Introduction: Advanced Chronic Liver Disease (ACLD) is a major cause of death for people with HIV (PWH). While viral hepatitis coinfections are largely responsible for this trend, non-alcoholic fatty liver disease (NAFLD) is an emerging concern for PWH. The contribution of NAFLD to ACLD among PWH remains unknown.

Methods and analysis: This multicenter prospective observational cohort study will enroll 968 consecutive HIV monoinfected patients from four Canadian sites. Individuals with excessive alcohol consumption, other causes of liver disease besides NAFLD, or with ACLD at baseline will be excluded. Participants will be followed annually for four years by clinical evaluation, questionnaires, laboratory testing and Fibroscan to measure liver stiffness measurement (LSM) and controlled attenuation parameter (CAP). The primary outcome will be the risk of incident ACLD, defined as $LSM > 10$ kPa, by NAFLD status, defined as $CAP \geq 285$ dB/m, and to develop a score to classify PWH according to their risk of ACLD. Secondary outcomes will include health-related quality of life (HRQoL) and healthcare resource utilization. Kaplan-Meier survival method and Cox proportional hazards regression will be employed to calculate the incidence and predictors of ACLD, respectively. Propensity score methods and marginal structural models will account for time-varying exposures. The full cohort will be split into a training set (to develop the risk score) and a validation set (for internal validation of the score). HRQoL scores and healthcare resource utilization will be compared by NAFLD status using generalized linear mixed effects model.

Ethics and dissemination: This protocol has been approved by the ethics committees of all participating institutions. Written informed consent will be obtained from all study participants. The results of this study will provide evidence to advocate for the inclusion of PWH in clinical trials of NAFLD-targeted therapies and case-finding of ACLD in PWH.

ARTICLE SUMMARY SECTION

Strengths and limitations of this study

- This will be a large prospective study assessing the role of NAFLD in the development of advanced chronic liver disease in consecutive people with HIV mono-infection in Canada.
- By developing a risk score to stratify people with HIV according to increased risk categories for advanced chronic liver disease, the results will have an impact on clinical practice. This risk score will also be used as an endpoint for future interventional studies.
- By investigating the effect of NAFLD on quality of life and healthcare resource utilization, the results will further establish the relevance of NAFLD in the setting of HIV.
- The study will provide evidence to advocate for equity and inclusion of people with HIV in global trials of new NAFLD-targeted molecules, and case finding of advanced chronic liver disease.
- Given the complexity of antiretroviral therapy (ART) exposure, we will not be powered to tease out the effect of single ART drugs; however, we will conduct sensitivity analyses to account for cumulative ART exposure and by class.

INTRODUCTION

With 62,790 people affected in Canada and more than 38 million worldwide, the human immunodeficiency virus (HIV) continues to be a major public health issue^{1,2}. Antiretroviral therapy (ART) has changed the prognosis of HIV infection, with a dramatic reduction in Acquired immunodeficiency syndrome (AIDS)-related deaths³. However, as people with HIV (PWH) age, the burden of non-AIDS related mortality rises⁴. Liver disease is a leading causes of non-AIDS related mortality^{5,6}. The recently proposed term Advanced Chronic Liver Disease (ACL D) reflects the continuum of advanced liver fibrosis and cirrhosis, emphasizing that portal hypertension, responsible for the majority of end-stage liver complications, may occur before a formal anatomical diagnosis of liver cirrhosis⁷. Liver fibrosis can be measured non-invasively using transient elastography by Fibroscan (Echosens, Paris, France), providing a safe and cost-effective identification of asymptomatic patients with ACL D at risk of developing hepatic decompensation and all-cause mortality⁸. Although liver biopsy remains the gold standard, according to the Baveno consensus liver stiffness measurement (LSM) by transient elastography is sufficient to suspect ACL D⁹. A variety of factors, including coinfection with hepatitis C (HCV) and hepatitis B (HBV) viruses, the high frequency of alcohol use, the hepatotoxicity of ART, and nonalcoholic fatty liver disease (NAFLD), contribute to ACL D in PWH¹⁰. HCV infection remains the leading cause of liver-related death in PWH, but the availability of highly effective new direct-acting antivirals has dwarfed the mortality trend¹¹. Conversely, NAFLD-related deaths in PWH are worryingly increasing, paralleling the raising prevalence of metabolic syndrome and other aging-related conditions¹¹. NAFLD is defined by the presence of fat in more than 5% of hepatocytes, in the absence of other causes of liver disease^{12,13}. It encompasses a range of conditions, from simple steatosis to nonalcoholic steatohepatitis (NASH), possibly evolving to liver fibrosis and ACL D,

ultimately leading to liver failure and hepatocellular carcinoma (HCC)^{12,13}. Affecting approximately 30% of the world's population, NAFLD is the most common liver disease globally and plays a central role in the epidemic of ACLD¹⁴. NAFLD is projected to become the leading indication for liver transplantation in North America in the next 10 years¹⁵. Beyond liver disease, NAFLD is emerging as a multisystem disease affecting extra-hepatic organs and a risk factor for all-cause mortality¹⁶. Furthermore, patients with NAFLD often experience a range of mental, emotional and social problems, resulting in impaired health-related quality of life (HRQoL)¹⁷. As a result, patients with NAFLD consume large amounts of healthcare resources¹⁸.

NAFLD is more common and severe in PWH compared to the general population¹⁹. Our cross-sectional data found a prevalence of NAFLD up to 48%, while ACLD seems four times more prevalent than in the general population^{20,21}. These findings are consistent with a recent meta-analysis in PWH reporting a prevalence of NAFLD on imaging studies at 34%, and a prevalence of biopsy-proven significant liver fibrosis at 23%²². This reflects the complex and multifaceted pathogenesis of NAFLD in PWH, with highly prevalent classical metabolic risk factors and unique HIV determinants, such as immune activation, virus-induced direct effect, systemic chronic inflammation and life-long exposure to ART¹⁹. Therefore, the European AIDS Clinical Society guidelines recommend the use of transient elastography or serum fibrosis biomarkers for case-finding of liver fibrosis and ACLD in PWH without viral hepatitis coinfection and with metabolic abnormalities, or elevation of liver transaminases or any exposure to dideoxynucleoside drugs (d-drugs) such as stavudine and didanosine²³. Nevertheless, hepatological societies still do not acknowledge HIV infection as a high-risk condition for NAFLD²⁴. PWH are excluded from global clinical trials of NAFLD-targeted therapies²⁵. Thus, there is a need for further high-quality

evidence on the role of NAFLD in the epidemic of ACLD in people with HIV mono-infection. In addition, to better allocate healthcare resources, it is clinically relevant to identify patients at high risk for progression to ACLD and thus develop an *ad hoc* risk score, incorporating HIV-related features. Finally, little is known about the impact of NAFLD on the HRQoL and the use of healthcare resources in PWH.

STUDY OBJECTIVES

Primary objectives

- To determine the risk of incident ACLD by NAFLD status (presence/absence) and by NAFLD severity as determined by LSM with controlled attenuation parameter (CAP) in PWH.
- To develop a risk score to classify PWH into increasing risk categories for development of ACLD based on identified predictors.

Secondary objectives

- To determine the effect of NAFLD on HRQoL in PWH.
- To determine the effect of NAFLD on healthcare resource utilization in PWH.
- To establish a tissue bank of plasma and serum from 150 participants as a resource for future studies of NAFLD, to better investigate correlations of additional known and unknown parameters with ACLD.

METHODS AND ANALYSIS

Study design

This study is a multicenter, prospective, observational cohort of PWH (LIVER disease in HIV [LIVEHIV] Cohort Study). Nine hundreds sixty-eight participants will be recruited from 4 sites in Canada including (1) the McGill University Health Centre (MUHC) (Montreal), (2) the Ottawa General Hospital, (3) the Toronto General Hospital and (4) the Oak Tree Clinic (Vancouver). These sites were selected because of the large number of diverse PWH they follow, the well-established research infrastructure with availability of LSM with CAP, and their history of successful enrollment in Canadian HIV Trials Network (CTN) studies.

Participants

Inclusion criteria

- (1) Age ≥ 18 years old; (2) historical HIV seropositive (ELISA with Western blot confirmation); (3) able to provide informed consent, in French or English.

Exclusion criteria

- (1) Presence of the outcome at baseline (ACLD); (2) liver decompensation; (3) contraindications to transient elastography (pregnancy or pacemaker); (4) unreliable LSM; (5) co-infection with HCV or HBV; (6) significant alcohol intake (Alcohol Use and Disorders Identification Test (AUDIT-C) score ≥ 4 in men and ≥ 3 in women²⁶); (7) autoimmune liver or cholestatic disease, hemochromatosis, Wilson disease, alpha-1-antitripsin deficiency; (8) pregnancy.

All PWH meeting eligibility criteria will be approached for participation consecutively, independently of known risk factors for the primary exposure (NAFLD) and outcome (ACLD).

Participant timeline

Participants will be followed on yearly basis after baseline visit for 4 years (Table 1). Participants will undergo an initial evaluation (baseline) followed by visits every 12 months (+/-2 month). In case of any complication during the course of study participation, such as liver decompensation, end-stage liver disease or $\text{LSM} \geq 15$ kPa, the follow-up visit will be changed to twice a year for 4 years and patients will undergo surveillance for HCC with ultrasound and serum alpha-fetoprotein, as well as consideration for esophagogastroduodenoscopy following the Baveno VII consensus criteria^{9,27}. HIV care providers will be notified of the finding of any complication occurred during study participation.

Outcome measures

Primary outcome

The primary outcome will be the development of ACLD, defined as $\text{LSM} > 10$ kPa, confirmed by a second transient elastography one week later. The main exposure will be NAFLD, defined as $\text{CAP} > 285$ dB/m at baseline, while severe NAFLD is defined as $\text{CAP} > 300$ dB/m.

Secondary outcomes

- HRQoL assessed by patient-reported outcome measures: Short Form-36 (SF-36) and Chronic Liver Disease Questionnaire (CLDQ).
- Healthcare resource utilization measured by self-reported questionnaires and linkage to provincial linked data.
- Development of end-stage liver disease (esophageal varices, hepatic encephalopathy, ascites, spontaneous bacterial peritonitis, hepatorenal syndrome, HCC, liver transplantation or liver-related death).

1

2

3 **Sample size**

4

5 We based the sample size calculation on a conservative prevalence of NAFLD in PWH of 36.4%

6 and our published rate of progression to significant liver fibrosis (stage 2) of 12.7 (95% CI, 9.5-

7 17.1) per 100 person-years (PY) over 4 years of follow-up^{21,28}. We expect a conservative incidence

8 rate of ACLD (stage 3 and 4) of 3.0 (95% CI, 1.1-5.5) vs. 1.2 per 100 PY (95% CI, 0.4-3.1) in

9 patients with and without NAFLD, respectively. Thus, the overall event rate would be 11% and

10 5% for ACLD over 4 years in patients with vs. without NAFLD, respectively. We require a sample

11 size of 880 with 4-years of follow-up to achieve 80% power to detect a hazard ratio (HR) of 2.0

12 with a type I error rate of 5%. We will increase our sample size to 968 to account for 10% potential

13 dropouts, loss to follow-up and Fibroscan failure or unreliable measurement (Figure 1).

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28 **Recruitment**

29

30 Patients will be informed about the study either during routine HIV clinic follow-up visits or during

31 transient elastography visits, and through established recruitment strategies by our community

32 partners and the CTN via websites, email, and social media platforms. All PWH meeting the

33 eligibility criteria will be approached for participation. To broaden generalizability, anyone who

34 meets the eligibility criteria may participate in the study if they can come to the enrollment sites

35 for the study visits. Potentially eligible candidates can be notified by following the instructions

36 provided on the CTN website²⁹. Participants will be compensated \$25 per study visit.

37

38

39

40

41

42

43

44

45

46

47

48

49 **Clinical, instrumental and laboratory evaluations**

50

51 *Clinical evaluations*

52

53

54

55

56

57

58

59

60

Once a participant has been identified for screening, the details of the study are carefully discussed with them. The participant will be asked to read and sign the approved informed consent form prior to any assessments being performed. Clinical assessment will include measurements of body mass index (BMI), waist circumference and blood pressure. Clinical charts will be reviewed to collect information about socio-demographic characteristics, past medical history (comorbidities and concomitant medications), and HIV-related variables (date of HIV diagnosis, date of initiation of ART, CD4 count nadir, history of antiretroviral treatment).

Transient elastography

Transient elastography examination will be performed on a 4-hour fasting participant. The same experienced operator (>100 examinations before the study) at each site, blinded to clinical and biological data, will perform 10 valid acquisitions of LSM and then the software of Fibroscan will calculate the median value²⁰. The standard M probe will be used in all patients. The XL probe will be used in patients with BMI>30 Kg/m² and in case of failure of Fibroscan examination by the M probe. The following manufacturer recommendations will be applied to define the result of Fibroscan as reliable: 10 validated measures, interquartile range <30% of the median³⁰. Presence of significant liver fibrosis and ACLD will be defined as LSM>7.1 kPa and LSM>10 kPa respectively^{9,31}. CAP measurement will be performed simultaneously to assess liver steatosis³². The following decisional cut-offs will be applied: no NAFLD (CAP<285 dB/m), mild NAFLD (CAP 285-300 dB/m), and severe NAFLD (CAP>300 dB/m)³³.

Questionnaires

Self-assessment questionnaires will be completed by participants at each visit to collect:

- Medical, sociodemographic and lifestyle information: AUDIT-C²⁶; substance use behavior; smoking habits; eating habits, tea and coffee use; physical activity; HIV adherence treatment scale.
- Patient reported outcomes and HRQoL: CLDQ and SF-36. The CLDQ is a validated liver disease specific quality of life index consisting of 29 items divided into six subscales and correlated with the severity of liver disease³⁴. Scores on the six subscales range from 1 to 7. An overall CLDQ score is then calculated (range = 1–7). Higher scores on each CLDQ scale reflect better HRQoL³⁵. The SF-36 consists of 36 questions that make up eight subscales³⁶. Within each dimension, 0 is the worst and 100 is the best possible score. An overall SF-36 score is then calculated, with a score greater or less than 50 representing better or poorer health than the general population, respectively³⁶.
- Healthcare resource utilization: report of number of visits to family medicine doctors, specialists, emergency rooms.

Participants who require help with reading and writing will be assisted by the study coordinators.

Laboratory test review

The results of the blood tests obtained for clinical evaluations at each visit as per routine standard of care will be reviewed. Routine hematology, chemistry and serological evaluations will include: liver function tests (alanine transaminase, aspartate aminotransferase, gamma-glutamyl transferase, alkaline phosphatase, total bilirubin, albumin, coagulation profile); complete blood count; biochemistry (fasting lipid profile, glucose and insulin, renal function tests); autoimmune markers (autoantibodies, immunoglobulins); serum ferritin and transferrin saturation; Hepatitis A,

B and C serology; HIV-related variables (plasma HIV RNA, absolute and relative CD4, nadir CD4, CD8 T-cell counts).

Biobanking Samples

Due to infrastructure constraints, biobanking samples will take place at the MUHC. Only plasma and serum from blood will be collected, and it will be stored for as long as the bank has a scientific interest to the community and the research team can ensure its management. To avoid multiple blood draws and visits, blood collection will be scheduled during routine clinical blood draw.

Statistical analyses

Primary analysis

Specific Aim 1: Determine the incidence of ACLD according to NAFLD status

The cumulative incidence of ACLD (primary outcome) will be calculated using the Kaplan-Meier survival method, comparing individuals with vs. without NAFLD, as assigned at baseline. A propensity score method will be applied to account for imbalances in the covariate distributions between participants with and without NAFLD at baseline using inverse probability weighting (IPW)^{37,38}. Next, to account for the time-varying nature of the exposure and confounders, we will use a multinomial logistic model using time-varying covariates to calculate IPW for the categorical exposure (NAFLD) to represent escalating severity of the disease. Marginal structural models with stabilized IPW weights will be calculated at each follow-up visit. We will use an absolute standardized mean difference of 0.1 as a cut-off. We hypothesize a dose-response of our exposure, meaning increased liver fat increases the risk of ACLD. Liver fat will be evaluated in three levels: no NAFLD (CAP<285 dB/m); mild NAFLD (CAP 285-300 dB/m); and severe NAFLD

(CAP>300 dB/m). To account for baseline liver fibrosis severity measured by transient elastography, we will also conduct a stratified analysis of the incidence of ACLD according to the baseline presence of significant liver fibrosis.

Specific aim 2: Develop a risk score to predict development of ACLD

The full cohort will be divided into a training set (to develop the risk score) and a validation set to internally validate the score. Associations of predictors with ACLD will be analyzed using Cox proportional hazards regression. Weights will be assigned for each predictor and the risk score will be computed as a linear combination of the weighted predictors^{39,40}. The 5-year risk of ACLD will be calculated by inserting the individual risk score into the survivor function from the proportional hazards model: $P(ACLD, 5y)_i = 1 - S_M(5y)^{\exp(RS_i - RS_m)}$ where SM = Survivor function estimate at 5 years and at means of all predictors, RS_i = individual risk score estimated as the linear combination of weighted predictors, and RSM = risk score estimated at means of all predictors. Departure from the proportional hazards assumption will be evaluated for all predictors based on Schoenfeld residuals. Apart from the full model defined a priori, we will fit a reduced model consisting of those predictors that were significantly related to ACLD in the full model and will test for possible interactions between various predictor variables (particularly by biological sex)⁴¹. Model performance will be evaluated by means of discrimination and calibration⁴². Discrimination is described by the c index for survival analysis, which quantifies the model's ability to separate persons with longer event-free survival from those with shorter event-free survival. In addition, we will compute the continuous net reclassification improvement (NRI) to compare the discriminatory ability of the different models. NRI values above 0.6 are considered strong, and values below 0.2, weak. For the category-based NRI, we will use 3 clinically relevant risk categories: low risk, <10%; medium risk, >10–25%; and high risk, >25%⁴³. The categories are

determined based on estimates of mortality from liver disease in those with chronic HCV infection from published reports, as well as opinions of knowledgeable hepatologists and clinicians^{44,45}. Calibration measures how well predicted probabilities agree with observed risks. We will present plots comparing observed proportions of events (from the validation sample) against average predicted probabilities across tenths of predicted risk. We will calculate sensitivity, specificity, positive predictive value, and negative predictive value for a range of potential cut-off points to define high-risk individuals. To find the optimal cut-off point, we will use the Youden index (J), defined as $J = \text{sensitivity} + \text{specificity} - 1$ ⁴⁶. It allows finding the threshold for which sensitivity and specificity are maximized.

Secondary Analysis

HRQoL scores and healthcare resource utilization will be compared by NAFLD status using generalized linear mixed effects model. Negative binomial regression analyses will also be used to ascertain how diagnosis relates to the HRQoL domains and to healthcare resource utilization, controlling for sex, ethnicity, BMI, Fibroscan score, diabetes and HIV-related variables (ART regimens, HIV viral load, CD4 cell count, nadir CD4).

ETHICS AND DISSEMINATION

Ethics

This study will be conducted in accordance with the Canadian Tri-Council Policy Statement Version 2 and the principles in the Declaration of Helsinki. Written informed consent will be obtained from all study participants. Patients at the MUHC will be invited to participate into the biobank sub-study. Participants who decline consent for biobanking study will be allowed to

participate in the cohort study only. At the time of initial manuscript submission (June 2023), the protocol of the LIVEHIV Cohort has been approved by the ethics committees of all participating institutions. Patient enrolment for this trial began in January 2022 at the MUHC, and it will begin in July 2023 at the other sites. Both the protocol and informed consent forms were reviewed and approved by the CTN Community Advisory Committee.

Availability of data and materials

All participant-related information will be kept confidential. All records will be kept in a secure, locked location only accessible to research staff. Participants will be identified only by a coded number specific to each participant. All computerized databases will identify participants by numeric codes only and will be password protected. Upon request, and in the presence of the investigator or his/her representative, participant records will be made available to the study sponsor, monitoring groups representative of the study sponsor, representatives of funding groups, and applicable regulatory agencies for the purpose of verification of clinical study procedures and/or data, as is permissible by local regulations. We will share research findings to the broader research communities by scientific and lay publications and through presentations at scientific conferences and community-based HIV clinics. A knowledge translation working group will systematically synthesize the findings of this study and tailor knowledge for identified stakeholders (decision makers, clinicians, PWH, and their advocates).

Patient and public involvement

Our team is committed to integrated knowledge translation by involving community members and PWH in the design and interpretation of the analysis, with two of the CTN co-applicants and co-

authors (C.P. and K.M.) being community member leaders in dissemination and advocacy for PWH. Community members were engaged in evaluating the research questions of this study, which were considered high priorities for PWH.

DISCUSSION

Herein, we present the protocol for a multicenter observational cohort study designed to evaluate the role of NAFLD in the development of ACLD in PWH and to develop a risk score to classify PWH according to their risk of incident ACLD. This study will also investigate the impact of NAFLD on HRQoL and healthcare resource utilization in PWH. The results of this study will be of immediate importance since PWH face inequities and disadvantages as they are currently excluded from global clinical trials of new NAFLD-targeted therapies able to halt the progression to ACLD and from case-finding strategies in NAFLD^{24,25}.

Whether NAFLD is a key player or a mere bystander of ACLD in HIV mono-infection is still a matter of debate^{47,48}. This knowledge gap is likely due to the complexity of factors that influence the development of both NAFLD and ACLD. Indeed, many factors contribute to the complex pathogenesis of ACLD in PWH (Figure 2). On one hand, metabolic disorders are increasing in PWH and contribute to the growing prevalence of NAFLD^{19,49}. Diabetes is four times more prevalent in HIV-positive vs. HIV-negative men⁵⁰. Dyslipidemia and hypertension are also very common^{4,51}. In this protocol, metabolic aspects related to NAFLD and ACLD are carefully considered, with markers of insulin resistance, lipid profile, and anthropometric measures collected and scheduled for analysis. We will also develop a risk score including metabolic parameters to predict which PWH are at high risk of ACLD. On the other hand, unique risk factors

may also contribute to ACLD in people with HIV mono-infection, who represent 86-89% of PWH¹⁰. First, the lifelong use of ART may result in liver fibrosis and oxidative stress in hepatocytes^{52,53}. Earlier nucleoside reverse transcriptase inhibitors, particularly d-drugs that are known to induce mitochondrial damage and impaired fatty acid oxidation in the hepatocytes, may have had a detrimental effect that could be realized as the population ages with HIV⁵⁴. Ritonavir-boosted protease inhibitors can lead to direct liver cell stress⁵⁵. Integrase strand transfer inhibitors (INSTI) may cause weight gain, although the metabolic and hepatic consequences of these newer agents is unknown, with one study suggesting INSTI as an independent predictor of incident hepatic steatosis⁵⁶, and others reporting reduced or no changes in liver fat after INSTI switching⁵⁷⁻⁵⁹. Longer observational studies are warranted to assess the effect of INSTI on the incidence of NAFLD in PWH. Second, HIV viremia from ART treatment interruptions is a risk factor for ACLD, as HIV itself may have pro-apoptotic effects on hepatocytes⁵². Given this complexity, we may find that We may find that exposure to ART, rather than NAFLD, is the major contributor to the development of ACLD in HIV mono-infected patients.. Should this be the case, our findings will still provide crucial information for subsequent monitoring and screening strategies for ACLD in PWH. Our prognostic score for development of ACLD will be modelled accordingly, by weighing on exposure to ART rather than NAFLD. Furthermore, our findings in Canada can serve as a model for other/different HIV realities, such as low/middle income countries, where ART is becoming widespread, resulting in an aging HIV-infected population and an increase in non-communicable diseases.

Although we will make careful ascertainment of covariates to control for potential confounders, and will employ sophisticated analysis to minimize biases, some issues may nevertheless arise.

- (1) We may encounter slower recruitment rate or higher loss to follow-up than expected. In this case, we will consider including 1-2 other HIV care centers through our close link to CTN.
- (2) We acknowledge the complexity of the ART exposure, and we will not be powered to tease out the effect of single ART drugs. However, we will conduct sensitivity analysis to account for cumulative ART exposure and by class, recent treatment interruptions and d-drugs exposure. Although not the primary aim, this cohort will be able to explore the effect of ART on incident ACLD, which can be used for future studies.
- (3) Our sample size will be limited to evaluate biological sex and the complexity of pre/post menopause as an effect modifier; however, our cohort will remain the largest sample of women with HIV attempting to address this research question. Our data will be crucial to advocate for inclusion of women in future studies.
- (4) We will be underpowered to assess outcomes with expected lower incidence (end-stage liver diseases) or to conduct a stratified analysis by baseline fibrosis stage. However, our study can be used to power subsequent larger-scale multicenter studies. We also plan to expand the LIVEHIV Cohort to an International Cohort through the Steatohepatitis in HIV Emerging Research (SHIVER) Network^{24,25,60}, with the purpose of assessing these rare outcomes, as well as validating externally the prognostic risk score.
- (5) The lack of a histologic diagnosis is a limitation. However, transient elastography provides a simultaneous point-of-care assessment of liver fat and fibrosis, and has been extensively validated in NAFLD^{61,62} and in PWH^{31,32,63}. Besides, non-invasive diagnostic tools are patient-friendly, cost-effective and help broaden the study generalizability and reduce selection biases.

(6) Most participants will be recruited from tertiary hospitals, with possible over-representation of complex cases and under-representation of marginalized patients, such as indigenous people. However, we will attempt to broaden generalizability by promoting the study through community partners and the CTN via websites, email, and social media.

In conclusion, our findings will demonstrate that HIV is a convergence for two epidemics, ACLD and NAFLD, thereby generating evidence to advocate for equity and inclusion of PWH in global trials of new antifibrotic molecules for NAFLD and case-finding of PWH at high risk of developing ACLD. Overall, we expect that our results will change clinical practice, policies and improve healthcare outcomes for PWH.

Funding

The study was funded by an operating grant from the Canadian Institute of Health Research (CIHR) and by the CIHR Canadian HIV Trials Network. W.E. has received PhD fellowship from the Canadian Network on Hepatitis C (CanHepC). CanHepC is funded by a joint initiative of the Canadian Institutes of Health Research (NPC-178912) and the Public Health Agency of Canada. S.W. is the Speck Family Chair in emerging infectious diseases. N.K. and C.Cos. are supported by a Fonds de Recherche du Québec – Santé (FRQS) Junior 2 career award. A.D.P. is supported by a Senior Salary Award from FRQS. BL is supported by 2 career awards: a Senior Salary Award from Fonds de recherche du Québec–Santé (FRQS) (#311200) and the LE 250 (from the Québec Ministry of Health for researchers in Family Medicine), from the Quebec’s Ministry of Health for researchers in Family Medicine and holds a Canadian Institutes for Health Research, Strategy for Patient-Oriented Research Mentorship Chair in Innovative Clinical Trials for HIV Care. J.P.R. is the holder of the Louis Lowenstein Chair in Hematology and Oncology, McGill University. G.S. is supported by a Senior Salary Award from FRQS (#296306).

Conflicts of interest

B.L. has acted as a speaker and advisory board member for ViiV, Gilead, and Merck, and received research funding from ViiV, Merck, and Gilead. C.Cos. has received research funding from Merck, Gilead and Tilray Inc, speaker honorarium from Gilead and consultant fees from ViiV Healthcare and Moderna. She has received funding to attend conferences from Gilead and ViiV Healthcare, and cannabinoids from Tilray Inc. for use in a clinical trial. S.W. has served on advisory board, and spoken at CME event for Merck, Gilead, Viiv, and has received research funds from ViiV, Gilead and Merck. M.C.M.M. has served on advisory boards and spoken at CME events for Merck,

Gilead and Viiv, and has received research funds from Viiv. G.S. has acted as speaker for Merck, Gilead, Abbvie, Novonordisk, Pfizer, served as an advisory board member for Pfizer, Merck, NovoNordisk, Gilead and Intercept and has received unrestricted research funding from Theratecnologies. F.C., S.S., D.K., L.R.B., W.E., E.E.M.M., C.P., K.M., N.P., N.K., A.D.P., J.P.R., M.B.K. have no conflict of interests.

Author statement

The principal investigator of the study is G.S. Site investigators of the study are M.B.K., C. Co., S.W., N.P., M.C.M.M. Other CTN co-applicants are S.S. (Methodologist), E.E.M.M. (Methodologist), K.M. (Community Representatives), C.P. (Community Representatives). G.S. conceived the study, led the proposal and protocol development. S.S. and E.E.M.M. provided methodological expertise and performed sample size calculations. F.C., D.K., L.R.B., W.E., B.L, N.K., C.Cos., J.P.R. and A.D.P. are involved in patient enrollment. F.C., S.S. and G.S. wrote the first draft of the manuscript. M.B.K., C. Co., S.W., E.E.M.M., N.P., M.C.M.M., D.K., L.R.B., W.E., B.L, N.K., C.Cos., J.P.R. and A.D.P. reviewed and edited the manuscript. All authors have read and agreed to the published version of the manuscript.

Table 1: Schedule of visits and procedures

Procedures:		Visit 1		Visit 2	Visit 3	Visit 4	Visit 5
		Screening	Baseline	Follow-Up (12 ± 3 months)	Follow-Up (24 ± 3 months)	Follow-Up (36 ± 3 months)	Follow-Up (48 ± 3 months)
Assessment of Eligibility		X					
Consent form		X	X	X	X	X	X
Fibroscan			X	X	X	X	X
Confirmation of Eligibility (includes Fibroscan result and AUDIT-C)			X				
Clinical Assessment	-Weight and Height to calculate BMI -Waist Circumference -Blood Pressure -Standard of Care Laboratory Tests		X	X	X	X	X
Biobanking	Plasma and serum sampling*		X				
Questionnaires	- Medical information questionnaire - Audit c - CLDQ & SF 36 (PROS-HRQoL) - HATS questionnaire - Health resource utilization questionnaire		X	X	X	X	X
Report Laboratory Tests	- Liver profile (ALT, AST, GGT, alkaline phosphatase, total bilirubin, albumin, coagulation profile) - Complete blood count, biochemistry; fasting lipid profile, glucose and insulin fasting for at least 12 hours prior to bloodwork - Autoimmune markers (AMA, ANA, anti-LKM, ASMA, immunoglobulins); serum ferritin and transferrin saturation - Plasma HIV RNA; lymphocyte subsets (absolute and relative CD4, nadir CD4, CD8 T-cell counts)		X	X	X	X	X

	- HAV, HBV and HCV serology (if not documented within 1 year of study entry)		X				
In the Case of ACLD	6-monthly serum alpha-fetoprotein and ultrasound in patients who develop ACLD (Fibroscan >10 kPa)			X	X	X	X
	Outcome Measure Form (End stage Liver disease Form)			X	X	X	X
Chart Review	- Medical history: report hepatic and HIV-related diagnoses - Antiretroviral history; report past and current ART - Concomitant Medications; report ongoing medications	X	X	X	X	X	X

*Sub-study for 150 participants consent to banking plasma and serum samples for the McGill University Health Centre only

Abbreviations: ACLD, advanced chronic liver disease; ALT, alanine aminotransferase; AMA, antimitochondrial antibody; ANA, antinuclear antibody; anti-LKM; anti-liver/kidney microsomal antibodies; ART, antiretroviral therapy; ASMA, anti-smooth muscle antibody; AST, aspartate aminotransferase; AUDIT-C, Alcohol Use and Disorders Identification Test C; BMI, body mass index; CLDQ, Chronic Liver Disease Questionnaire; HATS, HIV adherence treatment scale; HRQoL, health-related quality of life; GGT, gamma-glutamyl transferase; kPa, kilopascal; HAV, hepatitis A virus; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; PROs, Patient reported outcomes; SF-36, Short Form-36

References

1. Canada PHA of. Estimates of HIV incidence, prevalence and Canada's progress on meeting the 90-90-90 HIV targets, 2020 [Internet]. 2022 [cited 2023 May 15]. Available from: <https://www.canada.ca/en/public-health/services/publications/diseases-conditions/estimates-hiv-incidence-prevalence-canada-meeting-90-90-90-targets-2020.html>
2. Global HIV & AIDS statistics — Fact sheet [Internet]. [cited 2023 May 15]. Available from: <https://www.unaids.org/en/resources/fact-sheet>
3. Palella FJ, Loveless MO, Holmberg SD. Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus Infection. *The New England Journal of Medicine*. 1998;
4. Guaraldi G, Lonardo A, Maia L, Palella FJ. Metabolic concerns in aging HIV-infected persons: from serum lipid phenotype to fatty liver. *AIDS*. 2017 Jun 1;31(Supplement 2):S147–56.
5. Rosenthal E, Salmon-Céron D, Lewden C, Bouteloup V, Pialoux G, Bonnet F, et al. Liver-related deaths in HIV-infected patients between 1995 and 2005 in the French GERMIVIC Joint Study Group Network (Mortavic 2005 study in collaboration with the Mortalité 2005 survey, ANRS EN19). *HIV Med*. 2009 May;10(5):282–9.
6. Croxford S, Kitching A, Desai S, Kall M, Edelstein M, Skingsley A, et al. Mortality and causes of death in people diagnosed with HIV in the era of highly active antiretroviral therapy compared with the general population: an analysis of a national observational cohort. *The Lancet Public Health*. 2017 Jan;2(1):e35–46.
7. de Franchis R. Expanding consensus in portal hypertension. *Journal of Hepatology*. 2015 Sep;63(3):743–52.
8. Petta S, Sebastiani G, Viganò M, Ampuero J, Wai-Sun Wong V, Boursier J, et al. Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease. *Clinical Gastroenterology and Hepatology*. 2021 Apr;19(4):806-815.e5.
9. de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C, Abraldes JG, et al. Baveno VII – Renewing consensus in portal hypertension. *Journal of Hepatology*. 2022 Apr;76(4):959–74.
10. Kaspar MB, Sterling RK. Mechanisms of liver disease in patients infected with HIV. *BMJ Open Gastroenterol*. 2017 Oct 26;4(1):e000166.
11. Paik JM, Henry L, Golabi P, Alqahtani SA, Trimble G, Younossi ZM. Presumed Nonalcoholic Fatty Liver Disease Among Medicare Beneficiaries With HIV, 2006–2016. *Open Forum Infect Dis*. 2020 Jan 7;7(1):ofz509.

12. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. *Hepatology* [Internet]. 2023 Feb 3 [cited 2023 Feb 4];Publish Ahead of Print. Available from: <https://journals.lww.com/10.1097/HEP.0000000000000323>

13. EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. *Journal of Hepatology*. 2016 Jun;64(6):1388–402.

14. Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. *Hepatology*. 2023 Apr;77(4):1335–47.

15. Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA. Frequency and Outcomes of Liver Transplantation for Nonalcoholic Steatohepatitis in the United States. *Gastroenterology*. 2011 Oct;141(4):1249–53.

16. Byrne CD, Targher G. NAFLD: a multisystem disease. *J Hepatol*. 2015 Apr;62(1 Suppl):S47–64.

17. Golabi P, Otgonsuren M, Cable R, Felix S, Koenig A, Sayiner M, et al. Non-alcoholic Fatty Liver Disease (NAFLD) is associated with impairment of Health Related Quality of Life (HRQOL). *Health and Quality of Life Outcomes*. 2016 Feb 9;14(1):18.

18. Allen AM, Van Houten HK, Sangaralingham LR, Talwalkar JA, McCoy RG. Healthcare Cost and Utilization in Nonalcoholic Fatty Liver Disease: Real-World Data from a Large US Claims Database. *Hepatology*. 2018 Dec;68(6):2230–8.

19. Cervo A, Shengir M, Patel K, Sebastiani G. NASH in HIV. *Curr HIV/AIDS Rep*. 2020 Dec;17(6):601–14.

20. Vuille-Lessard É, Lebouché B, Lennox L, Routy JP, Costiniuk CT, Pexos C, et al. Nonalcoholic fatty liver disease diagnosed by transient elastography with controlled attenuation parameter in unselected HIV monoinfected patients. *AIDS*. 2016 Nov 13;30(17):2635–43.

21. Pembroke T, Deschenes M, Lebouché B, Benmassaoud A, Sewitch M, Ghali P, et al. Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV co-infected patients and is associated with liver fibrosis. *Journal of Hepatology*. 2017 Oct;67(4):801–8.

22. Kalligeros M, Vassilopoulos A, Shehadeh F, Vassilopoulos S, Lazaridou I, Mylonakis E, et al. Prevalence and Characteristics of Nonalcoholic Fatty Liver Disease and Fibrosis in People Living With HIV Monoinfection: A Systematic Review and Meta-analysis. *Clinical Gastroenterology and Hepatology*. 2023 Jan;S1542356523000289.

23. Ryom L, De Miguel R, Cotter AG, Podlekareva D, Beguelin C, Waalewijn H, et al. Major revision version 11.0 of the European AIDS Clinical Society Guidelines 2021. *HIV Med*. 2022 Sep;23(8):849–58.

24. Sebastiani G, Milic J, Tsochatzis EA, Marzolini C, Betel M, Bhagani S, et al. Letter to the editor: People living with HIV and NAFLD: A population left behind in the global effort for liver fibrosis screening? *Hepatology*. 2023 May 19;
25. Guaraldi G, Maurice JB, Marzolini C, Monteith K, Milic J, Tsochatzis E, et al. New Drugs for NASH and HIV Infection: Great Expectations for a Great Need. *Hepatology*. 2020 May;71(5):1831–44.
26. Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. *Arch Intern Med*. 1998 Sep 14;158(16):1789–95.
27. Loomba R, Lim JK, Patton H, El-Serag HB. AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review. *Gastroenterology*. 2020 May;158(6):1822–30.
28. Benmassaoud A, Nitulescu R, Pembroke T, Halme AS, Ghali P, Deschenes M, et al. Liver-related Events in Human Immunodeficiency Virus–infected Persons With Occult Cirrhosis. *Clin Infect Dis*. 2019 Oct 15;69(8):1422–30.
29. CTN 326: LIVEHIV Cohort Plus | Clinical Care and Management (CCM) [Internet]. CIHR Canadian HIV Trials Network. [cited 2023 Jun 6]. Available from: <https://www.hivnet.ubc.ca/study/ctn-326-livehiv-cohort-plus/>
30. Castera L. Noninvasive Methods to Assess Liver Disease in Patients With Hepatitis B or C. *Gastroenterology*. 2012 May;142(6):1293–1302.e4.
31. Morse CG, McLaughlin M, Proschan M, Koh C, Kleiner DE, Heller T, et al. Transient elastography for the detection of hepatic fibrosis in HIV-monoinfected adults with elevated aminotransferases on antiretroviral therapy. *AIDS*. 2015 Nov;29(17):2297–302.
32. Duarte M, Tien P, Ma Y, Noworolski SM, Korn N, Price JC. Controlled attenuation parameter accurately detects liver steatosis in people with HIV. *AIDS*. 2022 Dec 1;36(15):2147–52.
33. Ajmera VH, Cachay ER, Ramers CB, Bassirian S, Singh S, Bettencourt R, et al. Optimal Threshold of Controlled Attenuation Parameter for Detection of HIV-Associated NAFLD With Magnetic Resonance Imaging as the Reference Standard. *Clin Infect Dis*. 2020 Sep 25;72(12):2124–31.
34. Younossi ZM, Stepanova M, Henry L, Racila A, Lam B, Pham HT, et al. A disease-specific quality of life instrument for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: CLDQ-NAFLD. *Liver Int*. 2017 Aug;37(8):1209–18.
35. Younossi ZM, Guyatt G, Kiwi M, Boparai N, King D. Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. *Gut*. 1999 Aug 1;45(2):295–300.

36. Ware JE, Sherbourne CD. The MOS 36-Item Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection. *Medical Care*. 1992;30(6):473–83.

37. Austin PC. The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments. *Stat Med*. 2014 Mar 30;33(7):1242–58.

38. Mertens BJ, Datta S, Brand R, Peul W. Causal effect estimation strategies in a longitudinal study with complex time-varying confounders: A tutorial. *Stat Methods Med Res*. 2017 Feb;26(1):337–55.

39. Pavlou M, Ambler G, Seaman SR, Guttman O, Elliott P, King M, et al. How to develop a more accurate risk prediction model when there are few events. *BMJ*. 2015 Aug 11;351:h3868.

40. Ware JH. The limitations of risk factors as prognostic tools. *N Engl J Med*. 2006 Dec 21;355(25):2615–7.

41. Pepe MS, Feng Z, Huang Y, Longton G, Prentice R, Thompson IM, et al. Integrating the predictiveness of a marker with its performance as a classifier. *Am J Epidemiol*. 2008 Feb 1;167(3):362–8.

42. Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. *Circulation*. 2007 Feb 20;115(7):928–35.

43. Leening MJG, Vedder MM, Witteman JCM, Pencina MJ, Steyerberg EW. Net reclassification improvement: computation, interpretation, and controversies: a literature review and clinician’s guide. *Ann Intern Med*. 2014 Jan 21;160(2):122–31.

44. Hallager S, Brehm Christensen P, Ladelund S, Rye Clausen M, Lund Laursen A, Møller A, et al. Mortality Rates in Patients With Chronic Hepatitis C and Cirrhosis Compared With the General Population: A Danish Cohort Study. *J Infect Dis*. 2017 Jan 15;215(2):192–201.

45. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. *JAMA*. 2012 Dec 26;308(24):2584–93.

46. Chen F, Xue Y, Tan MT, Chen P. Efficient statistical tests to compare Youden index: accounting for contingency correlation. *Stat Med*. 2015 Apr 30;34(9):1560–76.

47. Cai J, Sebastiani G. HIV, Elevated Transaminases, Fatty Liver: The Perfect Storm? *J Acquir Immune Defic Syndr*. 2019 May 1;81(1):e23–5.

48. Iogna Prat L, Tsochatzis EA. Human Immunodeficiency Virus and Fatty Liver: The Perfect Storm or a Storm in a Teacup? *J Acquir Immune Defic Syndr*. 2019 May 1;81(1):e25–6.


49. Benmassaoud A, Ghali P, Cox J, Wong P, Szabo J, Deschenes M, et al. Screening for nonalcoholic steatohepatitis by using cytokeratin 18 and transient elastography in HIV mono-infection. *PLoS One*. 2018 Jan 30;13(1):e0191985.
50. Brown TT. Antiretroviral Therapy and the Prevalence and Incidence of Diabetes Mellitus in the Multicenter AIDS Cohort Study. *Arch Intern Med*. 2005 May 23;165(10):1179.
51. Sprinz E, Lazzaretti RK, Kuhmmer R, Ribeiro JP. Dyslipidemia in HIV-infected individuals. *The Brazilian Journal of Infectious Diseases*. 2010 Nov;14(6):575–88.
52. Kovari H, Weber R. Influence of antiretroviral therapy on liver disease: Current Opinion in HIV and AIDS. 2011 Jul;6(4):272–7.
53. Ingiliz P, Valantin MA, Duvivier C, Medja F, Dominguez S, Charlotte F, et al. Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy. *Hepatology*. 2009 Feb;49(2):436–42.
54. Merchante N, Pérez-Camacho I, Mira JA, Rivero A, Macías J, Camacho A, et al. Prevalence and risk factors for abnormal liver stiffness in HIV-infected patients without viral hepatitis coinfection: role of didanosine. *Antivir Ther*. 2010;15(5):753–63.
55. Sulkowski MS, Mehta SH, Chaisson RE, Thomas DL, Moore RD. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. *AIDS*. 2004 Nov 19;18(17):2277–84.
56. Bischoff J, Gu W, Schwarze-Zander C, Boesecke C, Wasmuth JC, Van Bremen K, et al. Stratifying the risk of NAFLD in patients with HIV under combination antiretroviral therapy (cART). *EClinicalMedicine*. 2021 Oct;40:101116.
57. Calza L, Colangeli V, Borderi M, Coladonato S, Tazza B, Fornaro G, et al. Improvement in liver steatosis after the switch from a ritonavir-boosted protease inhibitor to raltegravir in HIV-infected patients with non-alcoholic fatty liver disease. *Infect Dis (Lond)*. 2019 Aug;51(8):593–601.
58. Macías J, Mancebo M, Merino D, Téllez F, Montes-Ramírez ML, Pulido F, et al. Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among Human Immunodeficiency Virus–Infected Patients With Nonalcoholic Fatty Liver Disease. *Clinical Infectious Diseases*. 2017 Sep 15;65(6):1012–9.
59. Hanttu A, Vuoti S, Kivelä P, Arkkila P, Lundbom N, Hakkarainen A, et al. Liver Fat, Adipose Tissue, and Body Composition Changes After Switching from a Protease Inhibitor or Efavirenz to Raltegravir. *AIDS Patient Care STDS*. 2021 Sep;35(9):335–41.
60. Maurice JB, Goldin R, Hall A, Price JC, Sebastiani G, Morse CG, et al. Increased Body Mass Index and Type 2 Diabetes Are the Main Predictors of Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in Liver Biopsies of Patients With Human Immunodeficiency Virus Monoinfection. *Clin Infect Dis*. 2021 Oct 5;73(7):e2184–93.

61. Petroff D, Blank V, Newsome PN, Shalimar, Voican CS, Thiele M, et al. Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis. *The Lancet Gastroenterology & Hepatology*. 2021 Mar;6(3):185–98.

62. Friedrich-Rust M, Ong MF, Martens S, Sarrazin C, Bojunga J, Zeuzem S, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. *Gastroenterology*. 2008 Apr;134(4):960–74.


63. Lemoine M, Assoumou L, De Wit S, Girard PM, Valantin MA, Katlama C, et al. Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study. *J Acquir Immune Defic Syndr*. 2019 Apr 1;80(4):e86–94.

Figure 1: Sample size estimation.



Abbreviation: NAFLD, Non-alcoholic Fatty Liver Disease

Figure 2: Hypothetical pathogenesis of advanced chronic liver disease in HIV mono-infection.



Abbreviations: ACLD, advanced chronic liver disease; ART, antiretroviral therapy; HIV, human immunodeficiency virus; LIVEHIV, LIVER disease in HIV; NAFLD, Non-alcoholic Fatty Liver Disease

BMJ Open

The role of fatty liver in the epidemic of advanced chronic liver disease among people with HIV: protocol for the Canadian LIVEHIV multicenter prospective cohort

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2023-076547.R1
Article Type:	Protocol
Date Submitted by the Author:	04-Aug-2023
Complete List of Authors:	<p>CINQUE, FELICE; McGill University Health Centre, Chronic Viral Illness Service; McGill University Health Centre, Division of Gastroenterology and Hepatology</p> <p>Saeed, Sahar; Queen's University, Public Health Sciences</p> <p>Kablawi, Dana; McGill University Health Centre, Chronic Viral Illness Service; McGill University Health Centre, Division of Gastroenterology and Hepatology</p> <p>Ramos Ballesteros, Luz; McGill University Health Centre, Chronic Viral Illness Service; McGill University Health Centre, Division of Gastroenterology and Hepatology,</p> <p>Elgretli, Wesal; McGill University, Division of Experimental Medicine</p> <p>Moodie, Erica; McGill University, Department of Epidemiology, Biostatistics and Occupational Health</p> <p>Price, Colleen; Canadian HIV/AIDS and Chronic Pain Society</p> <p>Monteith, Ken; COCQ SIDA</p> <p>Cooper, Curtis; Ottawa Hospital Research Institute, Department of Medicine, Division of Infectious Diseases</p> <p>Walmsley, Sharon; University of Toronto, Department of Medicine, Division of Infectious Diseases</p> <p>Pick, Neora; The University of British Columbia</p> <p>Murray, Melanie; The University of British Columbia</p> <p>Cox, Joseph; McGill University Health Centre, Chronic Viral Illness Service; McGill University, Department of Epidemiology, Biostatistics and Occupational Health</p> <p>Kronfli, Nadine; McGill University Health Centre, Chronic Viral Illness Service</p> <p>Costiniuk, Cecilia T.; McGill University, Chronic Viral Illness Service</p> <p>de Pokomandy, Alexandra; McGill University Health Centre, Chronic Viral Illness Service</p> <p>Routy, Jean-Pierre; McGill University Health Centre, Chronic Viral Illness Service</p> <p>Lebouché, Bertrand; McGill University Faculty of Medicine and Health Sciences, Department of Family Medicine; McGill University Health Centre, Chronic Viral Illness Service</p> <p>Klein, Marina; McGill University Health Centre, Chronic Viral Illness Service; McGill University, Department of Epidemiology, Biostatistics and Occupational Health</p> <p>Sebastiani, Giada; McGill University Health Centre, Division of Gastroenterology and Hepatology; McGill University, Division of</p>

	Experimental Medicine
Primary Subject Heading:	HIV/AIDS
Secondary Subject Heading:	Gastroenterology and hepatology, Infectious diseases, Patient-centred medicine
Keywords:	HIV & AIDS < INFECTIOUS DISEASES, Hepatology < INTERNAL MEDICINE, Quality of Life, Patient-Centered Care

SCHOLARONE™
Manuscripts

The role of fatty liver in the epidemic of advanced chronic liver disease among people with HIV: protocol for the Canadian LIVEHIV multicenter prospective cohort

Felice Cinque^{1,2*}, Sahar Saeed^{3*}, Dana Kablawi^{1,2}, Luz Ramos Ballesteros^{1,2}, Wesal Elgretli⁴, Erica E.M. Moodie⁵, Colleen Price⁶, Ken Monteith⁷, Curtis Cooper⁸, Sharon Walmsley⁹, Neora Pick¹⁰, Melanie C.M. Murray¹⁰, Joseph Cox^{2,5}, Nadine Kronfli², Cecilia Costiniuk², Alexandra De Pokomandy², Jean-Pierre Routy², Bertrand Lebouche^{2,11}, Marina B. Klein^{2,5}, Giada Sebastiani^{1,2,4}

¹Division of Gastroenterology and Hepatology, McGill University Health Centre, Montreal, Canada

²Chronic Viral Illness Service, Division of Infectious Diseases, Department of Medicine, McGill University Health Centre, Montreal, Canada

³Public Health Sciences, Queen's University, Kingston, Canada

⁴Division of Experimental Medicine, McGill University, Montreal, Canada

⁵Department of Epidemiology, Biostatistics and Occupational Health, McGill University

⁶Canadian HIV/AIDS and Chronic Pain Society

⁷COCQ SIDA, Montreal, Canada

⁸Department of Medicine, Division of Infectious Diseases, The Ottawa Hospital, Ottawa Hospital Research Institute, Ottawa, Canada

⁹Department of Medicine, Division of Infectious Diseases, Toronto General Hospital, University of Toronto, Toronto, Canada

¹⁰University of British Columbia, Vancouver, Canada

¹¹Department of Family Medicine, Faculty of Medicine and Health Sciences, McGill University, Montreal, Quebec, Canada

* These authors equally contributed to this work.

Corresponding author’s contact information

Dr Giada Sebastiani, MD
Division of Gastroenterology and Hepatology; Chronic Viral Illness Service
Royal Victoria Hospital, McGill University Health Center
1001 Décarie Blvd.
Montreal, QC H4A 3J1, Canada.
Ph. (514) 843-1616; Fax (514) 843-1421
Email: giada.sebastiani@mcgill.ca

Keywords: HIV; Chronic liver disease, Fatty liver, Antiretroviral therapy, Health-related quality of life

Word count: abstract, 294; manuscript, 4330; Tables, 1; Figures, 2.

ABSTRACT

Introduction: Advanced Chronic Liver Disease (ACLD) is a major cause of death for people with HIV (PWH). While viral hepatitis coinfections are largely responsible for this trend, metabolic dysfunction-associated steatotic liver disease (MASLD) is an emerging concern for PWH. We aimed to assess the contribution of MASLD to incident ACLD in PWH.

Methods and analysis: This multicenter prospective observational cohort study will enroll 968 consecutive HIV monoinfected patients from four Canadian sites, excluding subjects with alcohol abuse, liver disease other than MASLD, or ACLD at baseline. Participants will be followed annually for four years by clinical evaluation, questionnaires, laboratory testing and Fibroscan to measure liver stiffness measurement (LSM) and controlled attenuation parameter (CAP). The primary outcome will be incidence of ACLD, defined as $LSM > 10$ kPa, by MASLD status, defined as $CAP \geq 285$ dB/m with at least one metabolic abnormality, and to develop a score to classify PWH according to their risk of ACLD. Secondary outcomes will include health-related quality of life (HRQoL) and healthcare resource utilization. Kaplan-Meier survival method and Cox proportional hazards regression will calculate the incidence and predictors of ACLD, respectively. Propensity score methods and marginal structural models will account for time-varying exposures. We will split the cohort into a training set (to develop the risk score) and a validation set (for validation of the score). HRQoL scores and healthcare resource utilization will be compared by MASLD status using generalized linear mixed effects model.

Ethics and dissemination: This protocol has been approved by the ethics committees of all participating institutions. Written informed consent will be obtained from all study participants. The results of this study will be shared through scientific publications and public presentations to

INTRODUCTION

With 62,790 people affected in Canada and more than 38 million worldwide, the human immunodeficiency virus (HIV) continues to be a major public health issue[1,2]. Antiretroviral therapy (ART) has changed the prognosis of HIV infection, with a dramatic reduction in Acquired immunodeficiency syndrome (AIDS)-related deaths[3]. However, as people with HIV (PWH) age, the burden of non-AIDS related mortality rises[4]. Liver disease is one of the leading causes of non-AIDS related mortality[5,6]. The recently proposed term Advanced Chronic Liver Disease (ACLD) reflects the continuum of advanced liver fibrosis and cirrhosis, emphasizing that portal hypertension, responsible for the majority of end-stage liver complications, may occur before a formal anatomical diagnosis of liver cirrhosis[7]. Liver fibrosis can be measured non-invasively using transient elastography by Fibroscan (Echosens, Paris, France), providing a safe and cost-effective identification of asymptomatic patients with ACLD at risk of developing hepatic decompensation and all-cause mortality[8]. Although liver biopsy remains the gold standard, according to the Baveno consensus liver stiffness measurement (LSM) by transient elastography is sufficient to suspect ACLD[9]. A variety of factors, including coinfection with hepatitis C (HCV) and hepatitis B (HBV) viruses, the high frequency of alcohol use, the hepatotoxicity of ART, and metabolic dysfunction-associated steatotic liver disease (MASLD), contribute to ACLD in PWH[10]. HCV infection remains the leading cause of liver-related death in PWH, but the availability of highly effective new direct-acting antivirals has dwarfed the mortality trend[11]. Conversely, MASLD-related deaths in PWH are worryingly increasing, paralleling the raising prevalence of metabolic syndrome and other aging-related conditions[11]. In June 2023, an international consensus panel introduced Steatotic liver disease (SLD) as an umbrella term encompassing the various etiologies of hepatic steatosis[12]. MASLD, formerly known as non-

alcoholic fatty liver disease, is defined as evidence of hepatic steatosis with at least one cardiometabolic risk factor, in the absence of excessive alcohol intake or other known causes of SLD[12]. It encompasses a range of conditions, from simple steatosis to metabolic dysfunction-associated steatohepatitis, possibly evolving to liver fibrosis and ACLD, ultimately leading to liver failure and hepatocellular carcinoma (HCC)[13,14]. Affecting approximately 30% of the world's population, MASLD is the most common liver disease globally and plays a central role in the epidemic of ACLD[15]. MASLD is projected to become the leading indication for liver transplantation in North America in the next 10 years[16]. Beyond liver disease, MASLD is emerging as a multisystem disease affecting extra-hepatic organs and a risk factor for all-cause mortality[17]. Furthermore, patients with MASLD often experience a range of mental, emotional and social problems, resulting in impaired health-related quality of life (HRQoL)[18]. As a result, patients with MASLD consume large amounts of healthcare resources[19].

MASLD is more common and severe in PWH compared to the general population[20]. Our cross-sectional data found a prevalence of MASLD up to 48%, while ACLD seems four times more prevalent than in the general population[21,22]. These findings are consistent with a recent meta-analysis in PWH reporting a prevalence of MASLD on imaging studies at 34%, and a prevalence of biopsy-proven significant liver fibrosis at 23%[23]. This reflects the complex and multifaceted pathogenesis of MASLD in PWH, with highly prevalent classical metabolic risk factors and unique HIV determinants, such as immune activation, virus-induced direct effect, systemic chronic inflammation and life-long exposure to ART[20]. Therefore, the European AIDS Clinical Society guidelines recommend the use of transient elastography or serum fibrosis biomarkers for case-finding of liver fibrosis and ACLD in PWH without viral hepatitis coinfection and with metabolic

1
2
3 abnormalities, or elevation of liver transaminases or any exposure to dideoxynucleoside drugs (d-
4
5 drugs) such as stavudine and didanosine[24]. Nevertheless, hepatological societies still do not
6
7 acknowledge HIV infection as a high-risk condition for MASLD[25]. PWH are excluded from
8
9 global clinical trials of MASLD-targeted therapies[26]. Thus, there is a need for further high-
10
11 quality evidence on the role of MASLD in the epidemic of ACLD in people with HIV mono-
12
13 infection. In addition, to better allocate healthcare resources, it is clinically relevant to identify
14
15 patients at high risk for progression to ACLD and thus develop an *ad hoc* risk score, incorporating
16
17 HIV-related features. Finally, little is known about the impact of MASLD on the HRQoL and the
18
19 use of healthcare resources in PWH.
20
21
22
23
24
25

26 STUDY OBJECTIVES

27 Primary objectives

- 28 - To determine the risk of incident ACLD by MASLD status (presence/absence) and by MASLD
29 severity as determined by LSM with controlled attenuation parameter (CAP) in PWH.
- 30 - To develop a risk score to classify PWH into increasing risk categories for development of ACLD
31 based on identified predictors.

32 Secondary objectives

- 33 - To determine the effect of MASLD on HRQoL in PWH.
- 34 - To determine the effect of MASLD on healthcare resource utilization in PWH.
- 35 - To establish a tissue bank of plasma and serum from 150 participants as a resource for future
36 studies of MASLD, to better investigate correlations of additional known and unknown parameters
37 with ACLD.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

METHODS AND ANALYSIS

Study design

This study is a multicenter, prospective, observational cohort of PWH (LIVER disease in HIV [LIVEHIV] Cohort Study). Nine hundreds sixty-eight participants will be recruited from 4 sites in Canada including (1) the McGill University Health Centre (MUHC) (Montreal), (2) the Ottawa General Hospital, (3) the Toronto General Hospital and (4) the Oak Tree Clinic (Vancouver). These sites were selected because of the large number of diverse PWH they follow, the well-established research infrastructure with availability of LSM with CAP, and their history of successful enrollment in Canadian HIV Trials Network (CTN) studies.

Participants

Inclusion criteria

- (1) Age ≥ 18 years old; (2) historical HIV seropositive (ELISA with Western blot confirmation); (3) able to provide informed consent, in French or English.

Exclusion criteria

- (1) Presence of the outcome at baseline (ACLD); (2) liver decompensation; (3) contraindications to transient elastography (pregnancy or pacemaker); (4) unreliable LSM (interquartile range [IQR] $>30\%$, less than 10 validated measures); (5) co-infection with HCV or HBV; (6) significant alcohol intake (Alcohol Use and Disorders Identification Test (AUDIT-C) score ≥ 4 in men and ≥ 3 in women[27]); (7) autoimmune liver or cholestatic disease, hemochromatosis, Wilson disease, alpha-1-antitripsin deficiency; (8) pregnancy.

All PWH meeting eligibility criteria will be approached for participation consecutively, independently of known risk factors for the primary exposure (MASLD) and outcome (ACLD).

Participant timeline

Participants will be followed on yearly basis after baseline visit for 4 years (Table 1). Participants will undergo an initial evaluation (baseline) followed by visits every 12 months (+/-2 month). In case of any complication during the course of study participation, such as liver decompensation, end-stage liver disease or $\text{LSM} \geq 15$ kPa, the follow-up visit will be changed to twice a year for 4 years and patients will undergo surveillance for HCC according to each site's protocol for the management of patients with ACLD, consisting of ultrasound and serum alpha-fetoprotein, as well as consideration for esophagogastroduodenoscopy following the Baveno VII consensus criteria[9,28]. HIV care providers will be notified of the finding of any complication occurred during study participation.

Outcome measures

Primary outcome

The primary outcome will be the development of ACLD, defined as $\text{LSM} > 10$ kPa, confirmed by a second transient elastography one week later. The main exposure will be MASLD, defined according to the recent multi-society Delphi consensus statement, as the presence of hepatic steatosis, defined as $\text{CAP} > 285$ dB/m, plus at least one out of five cardiometabolic criteria ([1] overweight or waist circumference > 94 cm for man and > 80 cm for women; [2] fasting serum glucose ≥ 5.6 mmol/L or 2-hour post-load glucose levels ≥ 7.8 mmol/L or hemoglobin glycosylated $\geq 5.7\%$ or type 2 diabetes or treatment for type 2 diabetes; [3] blood pressure $\geq 130/85$ mmHg or specific antihypertensive drug treatment; [4] plasma triglycerides ≥ 1.70 mmol/L or lipid lowering

treatment; [5] plasma high-density lipoprotein-cholesterol ≤ 1.0 mmol/L in men and ≤ 1.3 mmol/L in women, or lipid lowering treatment) and no other discernible causes of SLD[12]. Severe MASLD is defined as CAP>300 dB/m[29].

Secondary outcomes

- HRQoL assessed by patient-reported outcome measures: Short Form-36 (SF-36) and Chronic Liver Disease Questionnaire (CLDQ).
- Healthcare resource utilization measured by self-reported questionnaires and linkage to provincial linked data.
- Development of end-stage liver disease and cardiovascular disease.

Sample size

We based the sample size calculation on a conservative prevalence of MASLD in PWH of 36.4% and our published rate of progression to significant liver fibrosis (stage 2) of 12.7 (95% CI, 9.5-17.1) per 100 person-years (PY) over 4 years of follow-up[22,30]. We expect a conservative incidence rate of ACLD (stage 3 and 4) of 3.0 (95% CI, 1.1-5.5) vs. 1.2 per 100 PY (95% CI, 0.4-3.1) in patients with and without MASLD, respectively. Thus, the overall event rate would be 11% and 5% for ACLD over 4 years in patients with vs. without MASLD, respectively. We require a sample size of 880 with 4-years of follow-up to achieve 80% power to detect a hazard ratio (HR) of 2.0 with a type I error rate of 5%. We will increase our sample size to 968 to account for 10% potential dropouts, loss to follow-up and Fibroscan failure or unreliable measurement (Figure 1).

Recruitment

Patients will be informed about the study either during routine HIV clinic follow-up visits or during transient elastography visits, and through established recruitment strategies by our community partners and the CTN via websites, email, and social media platforms. All PWH meeting the eligibility criteria will be approached for participation. To broaden generalizability, anyone who meets the eligibility criteria may participate in the study if they can come to the enrollment sites for the study visits. Potentially eligible candidates can be notified by following the instructions provided on the CTN website[31]. Participants will be compensated \$25 per study visit.

Clinical, instrumental and laboratory evaluations

Clinical evaluations

Once a participant has been identified for screening, the details of the study are carefully discussed with them. The participant will be asked to read and sign the approved informed consent form prior to any assessments being performed. Clinical assessment will include measurements of body mass index (BMI), waist circumference and hip circumference to calculate waist-to-hip ratio, and blood pressure. Clinical charts will be reviewed to collect information about socio-demographic characteristics, past medical history (comorbidities and concomitant medications), HIV-related variables (date of HIV diagnosis, date of initiation of ART, CD4 count nadir, history of antiretroviral treatment), development of end-stage liver disease (esophageal varices, hepatic encephalopathy, ascites, spontaneous bacterial peritonitis, hepatorenal syndrome, HCC, liver transplantation or liver-related death) and development of cardiovascular disease (myocardial infarction, angina, stroke, or peripheral arterial disease).

Transient elastography and serum fibrosis biomarkers

Transient elastography examination will be performed on a 6-hour fasting participant who has been informed to avoid strenuous exercise prior to testing. Four certified operators (>100 examinations before the study), one per site, blinded to clinical and biological data, will perform 10 valid acquisitions of LSM and then the software of Fibroscan will calculate the median value[21]. The standard M probe will be used in all patients. The XL probe will be used in patients with BMI>30 Kg/m² and in case of failure of Fibroscan examination by the M probe. The following manufacturer recommendations will be applied to define the result of Fibroscan as reliable: 10 validated measures, interquartile range <30% of the median[32]. Presence of significant liver fibrosis and ACLD will be defined as LSM>7.1 kPa and LSM>10 kPa respectively[9,33]. CAP measurement will be performed simultaneously to assess liver steatosis[34]. The following decisional cut-offs will be applied: no MASLD (CAP<285 dB/m), mild MASLD (CAP 285-300 dB/m), and severe MASLD (CAP>300 dB/m)[29]. We will also compute the serum fibrosis biomarkers AST-to-Platelet Ratio index (APRI) and fibrosis-4 index (FIB-4), as previously described in PWH [35].

Questionnaires

Self-assessment questionnaires will be completed by participants at each visit to collect:

- Medical, sociodemographic and lifestyle information: AUDIT-C[27]; eating habits assessed by the food frequency questionnaire – short form (FFQ-SF)[36]; physical activity assessed by the International physical activity questionnaire – short form (IPAQ-SF)[37,38]; substance use behavior; smoking habits; tea and coffee use; HIV adherence treatment scale.
- Patient reported outcomes and HRQoL: CLDQ and SF-36. The CLDQ is a validated liver disease specific quality of life index consisting of 29 items divided into six subscales and

correlated with the severity of liver disease[39]. Scores on the six subscales range from 1 to 7. An overall CLDQ score is then calculated (range = 1–7). Higher scores on each CLDQ scale reflect better HRQoL[40]. The SF-36 consists of 36 questions that make up eight subscales[41]. Within each dimension, 0 is the worst and 100 is the best possible score. An overall SF-36 score is then calculated, with a score greater or less than 50 representing better or poorer health than the general population, respectively[41].

- Healthcare resource utilization: report of number of visits to family medicine doctors, specialists, emergency rooms.

Participants who require help with reading and writing will be assisted by the study coordinators.

Laboratory test review

The results of the blood tests obtained for clinical evaluations at each visit as per routine standard of care will be reviewed. Routine hematology, chemistry and serological evaluations will include: liver function tests (alanine transaminase, aspartate aminotransferase, gamma-glutamyl transferase, alkaline phosphatase, total bilirubin, albumin, coagulation profile); complete blood count; biochemistry (fasting lipid profile, glucose, insulin and glycosylated hemoglobin, renal function tests); autoimmune markers (autoantibodies, immunoglobulins); serum ferritin and transferrin saturation; Hepatitis A, B and C serology; HIV-related variables (plasma HIV RNA, absolute and relative CD4, nadir CD4, CD8 T-cell counts, CD4/CD8 ratio).

Biobanking Samples

Due to infrastructure constraints, biobanking samples will take place at the MUHC. Only plasma and serum from blood will be collected, and it will be stored for as long as the bank has a scientific

interest to the community and the research team can ensure its management. To avoid multiple blood draws and visits, blood collection will be scheduled during routine clinical blood draw.

Statistical analyses

Primary analysis

Specific Aim 1: Determine the incidence of ACLD according to MASLD status

The cumulative incidence of ACLD (primary outcome) will be calculated using the Kaplan-Meier survival method, comparing individuals with vs. without MASLD, as assigned at baseline. A propensity score method will be applied to account for imbalances in the covariate distributions between participants with and without MASLD at baseline using inverse probability weighting (IPW)[42,43]. Next, to account for the time-varying nature of the exposure and confounders, we will use a multinomial logistic model using time-varying covariates to calculate IPW for the categorical exposure (MASLD) to represent escalating severity of the disease. Marginal structural models with stabilized IPW weights will be calculated at each follow-up visit. We will use an absolute standardized mean difference of 0.1 as a cut-off. We hypothesize a dose-response of our exposure, meaning increased liver fat increases the risk of ACLD. Liver fat will be evaluated in three levels: no MASLD (CAP<285 dB/m); mild MASLD (CAP 285-300 dB/m); and severe MASLD (CAP>300 dB/m). To account for baseline liver fibrosis severity measured by transient elastography, we will also conduct a stratified analysis of the incidence of ACLD according to the baseline presence of significant liver fibrosis.

Specific aim 2: Develop a risk score to predict development of ACLD

The full cohort will be divided into a training set (to develop the risk score) and a validation set to internally validate the score. Associations of predictors with ACLD will be analyzed using Cox proportional hazards regression. Weights will be assigned for each predictor and the risk score will be computed as a linear combination of the weighted predictors[44,45]. The 5-year risk of ACLD will be calculated by inserting the individual risk score into the survivor function from the proportional hazards model: $P(ACLD, 5y)_i = 1 - S_M(5y)^{\exp(RS_i - RS_m)}$ where SM = Survivor function estimate at 5 years and at means of all predictors, RS_i = individual risk score estimated as the linear combination of weighted predictors, and RSM = risk score estimated at means of all predictors. Departure from the proportional hazards assumption will be evaluated for all predictors based on Schoenfeld residuals. Apart from the full model defined a priori, we will fit a reduced model consisting of those predictors that were significantly related to ACLD in the full model and will test for possible interactions between various predictor variables (particularly by biological sex)[46]. Model performance will be evaluated by means of discrimination and calibration[47]. Discrimination is described by the c index for survival analysis, which quantifies the model's ability to separate persons with longer event-free survival from those with shorter event-free survival. In addition, we will compute the continuous net reclassification improvement (NRI) to compare the discriminatory ability of the different models. NRI values above 0.6 are considered strong, and values below 0.2, weak. For the category-based NRI, we will use 3 clinically relevant risk categories: low risk, <10%; medium risk, >10–25%; and high risk, >25%[48]. The categories are determined based on estimates of mortality from liver disease in those with chronic HCV infection from published reports, as well as opinions of knowledgeable hepatologists and clinicians[49,50]. Calibration measures how well predicted probabilities agree with observed risks. We will present plots comparing observed proportions of events (from the validation sample)

against average predicted probabilities across tenths of predicted risk. We will calculate sensitivity, specificity, positive predictive value, and negative predictive value for a range of potential cut-off points to define high-risk individuals. To find the optimal cut-off point, we will use the Youden index (J), defined as $J = \text{sensitivity} + \text{specificity} - 1$ [51]. It allows finding the threshold for which sensitivity and specificity are maximized.

Secondary Analysis

HRQoL scores and healthcare resource utilization will be compared by MASLD status using generalized linear mixed effects model. Negative binomial regression analyses will also be used to ascertain how diagnosis relates to the HRQoL domains and to healthcare resource utilization, controlling for sex, ethnicity, BMI, Fibroscan score, diabetes and HIV-related variables (ART regimens, HIV viral load, CD4 cell count, nadir CD4).

ETHICS AND DISSEMINATION

Ethics

This study will be conducted in accordance with the Canadian Tri-Council Policy Statement Version 2 and the principles in the Declaration of Helsinki. Written informed consent will be obtained from all study participants. Patients at the MUHC will be invited to participate into the biobank sub-study. Participants who decline consent for biobanking study will be allowed to participate in the cohort study only. At the time of initial manuscript submission (June 2023), the protocol of the LIVEHIV Cohort has been approved by the ethics committees of all participating institutions: (1) MUHC Research Ethics Board (REB), (2) Ottawa Health Science Network REB, (3) University Health Network REB, (4) the Oak Valley Health REB. Patient enrolment for this trial began in January 2022 at the MUHC, and it will begin in July 2023 at the other sites. Both the

protocol and informed consent forms were reviewed and approved by the CTN Community Advisory Committee.

Availability of data and materials

All participant-related information will be kept confidential. All records will be kept in a secure, locked location only accessible to research staff. Participants will be identified only by a coded number specific to each participant. All computerized databases will identify participants by numeric codes only and will be password protected. Upon request, and in the presence of the investigator or his/her representative, participant records will be made available to the study sponsor, monitoring groups representative of the study sponsor, representatives of funding groups, and applicable regulatory agencies for the purpose of verification of clinical study procedures and/or data, as is permissible by local regulations.

Dissemination

We will share research findings to the broader research communities by scientific and lay publications and through presentations at scientific conferences and community-based HIV clinics. A knowledge translation working group will systematically synthesize the findings of this study and tailor knowledge for identified stakeholders (decision makers, clinicians, PWH, and their advocates).

Patient and public involvement

Our team is committed to integrated knowledge translation by involving community members and PWH in the design and interpretation of the analysis, with two of the CTN co-applicants and co-authors (C.P. and K.M.) being community member leaders in dissemination and advocacy for PWH. Community members were engaged in evaluating the research questions of this study, which were considered high priorities for PWH.

DISCUSSION

Herein, we present the protocol for a multicenter observational cohort study designed to evaluate the role of MASLD in the development of ACLD in PWH and to develop a risk score to classify PWH according to their risk of incident ACLD. This study will also investigate the impact of MASLD on HRQoL and healthcare resource utilization in PWH. The results of this study will be of immediate importance since PWH face inequities and disadvantages as they are currently excluded from global clinical trials of new MASLD-targeted therapies able to halt the progression to ACLD and from case-finding strategies in MASLD[25,26].

Whether MASLD is a key player or a mere bystander of ACLD in HIV mono-infection is still a matter of debate[52,53]. This knowledge gap is likely due to the complexity of factors that influence the development of both MASLD and ACLD. Indeed, many factors contribute to the complex pathogenesis of ACLD in PWH (Figure 2). On one hand, metabolic disorders are increasing in PWH and contribute to the growing prevalence of MASLD[20,54]. Diabetes is four times more prevalent in HIV-positive vs. HIV-negative men[55]. Dyslipidemia and hypertension are also very common[4,56]. In this protocol, metabolic aspects related to MASLD and ACLD are carefully considered, with markers of insulin resistance, lipid profile, anthropometric measures

and concomitant antidiabetic drugs collected and scheduled for analysis. We will also develop a risk score including metabolic parameters to predict which PWH are at high risk of ACLD. On the other hand, unique risk factors may also contribute to ACLD in people with HIV mono-infection, who represent 86-89% of PWH[10]. First, the lifelong use of ART may result in liver fibrosis and oxidative stress in hepatocytes[57,58]. Earlier nucleoside reverse transcriptase inhibitors, particularly d-drugs that are known to induce mitochondrial damage and impaired fatty acid oxidation in the hepatocytes, may have had a detrimental effect that could be realized as the population ages with HIV[59]. Ritonavir-boosted protease inhibitors can lead to direct liver cell stress[60]. Integrase strand transfer inhibitors (INSTI) and tenofovir alafenamide (TAF) may cause weight gain, although the metabolic and hepatic consequences of these newer agents is unknown, with one study suggesting INSTI and TAF as independent predictors of incident hepatic steatosis[61], and others reporting reduced or no changes in liver fat after INSTI switching[62–64]. Longer observational studies are warranted to assess the effect of INSTI on the incidence of MASLD in PWH. Second, HIV viremia from ART treatment interruptions is a risk factor for ACLD, as HIV itself may have pro-apoptotic effects on hepatocytes[57]. Given this complexity, we may find that exposure to ART, rather than MASLD, is the major contributor to the development of ACLD in HIV mono-infected patients. Should this be the case, our findings will still provide crucial information for subsequent monitoring and screening strategies for ACLD in PWH. Our prognostic score for development of ACLD will be modelled accordingly, by weighing on exposure to ART rather than MASLD. Furthermore, our findings in Canada can serve as a model for other/different HIV realities, such as low/middle income countries, where ART is becoming widespread, resulting in an aging HIV-infected population and an increase in non-communicable diseases.

Although we will make careful ascertainment of covariates to control for potential confounders, and will employ sophisticated analysis to minimize biases, some issues may nevertheless arise.

- (1) We may encounter slower recruitment rate or higher loss to follow-up than expected. In this case, we will consider including 1-2 other HIV care centers through our close link to CTN.
- (2) We acknowledge the complexity of the ART exposure, and we will not be powered to tease out the effect of single ART drugs. However, we will conduct sensitivity analysis to account for cumulative ART exposure and by class, recent treatment interruptions and drugs exposure. Although not the primary aim, this cohort will be able to explore the effect of ART on incident ACLD, which can be used for future studies. Special attention will be given to INSTI and TAF in the sensitivity analysis, considering the current open debate on weight gain and/or their role in MASLD development and progression to ACLD in PWH.
- (3) Our sample size will be limited to evaluate biological sex and the complexity of pre/post menopause as an effect modifier; however, our cohort will remain the largest sample of women with HIV attempting to address this research question. Our data will be crucial to advocate for inclusion of women in future studies.
- (4) We will be underpowered to assess outcomes with expected lower incidence (end-stage liver diseases) or to conduct a stratified analysis by baseline fibrosis stage. However, our study can be used to power subsequent larger-scale multicenter studies. We also plan to expand the LIVEHIV Cohort to an International Cohort through the Steatohepatitis in HIV Emerging Research (SHIVER) Network[25,26,65], with the purpose of assessing these rare outcomes, as well as validating externally the prognostic risk score.

- (5) The lack of a histologic diagnosis is a limitation. However, transient elastography provides a simultaneous point-of-care assessment of liver fat and fibrosis, and has been extensively validated in MASLD[66,67] and in PWH[33,34,68]. Besides, non-invasive diagnostic tools are patient-friendly, cost-effective and help broaden the study generalizability and reduce selection biases. We will also compute and follow longitudinally validated serum fibrosis biomarkers.
- (6) Most participants will be recruited from tertiary hospitals, with possible over-representation of complex cases and under-representation of marginalized patients, such as indigenous people. However, we will attempt to broaden generalizability by promoting the study through community partners and the CTN via websites, email, and social media.

In conclusion, our findings will demonstrate that HIV is a convergence for two epidemics, ACLD and MASLD, thereby generating evidence to advocate for equity and inclusion of PWH in global trials of new antifibrotic molecules for MASD and case-finding of PWH at high risk of developing ACLD. Overall, we expect that our results will change clinical practice, policies and improve healthcare outcomes for PWH.

Funding

The study was funded by an operating grant from the Canadian Institute of Health Research (CIHR) and by the CIHR Canadian HIV Trials Network. W.E. has received PhD fellowship from the Canadian Network on Hepatitis C (CanHepC). CanHepC is funded by a joint initiative of the Canadian Institutes of Health Research (NPC-178912) and the Public Health Agency of Canada. S.W. is the Speck Family Chair in emerging infectious diseases. N.K. and C.Cos. are supported by a Fonds de Recherche du Québec – Santé (FRQS) Junior 2 career award. A.D.P. is supported by a Senior Salary Award from FRQS. BL is supported by 2 career awards: a Senior Salary Award from Fonds de recherche du Québec–Santé (FRQS) (#311200) and the LE 250 (from the Québec Ministry of Health for researchers in Family Medicine), from the Quebec’s Ministry of Health for researchers in Family Medicine and holds a Canadian Institutes for Health Research, Strategy for Patient-Oriented Research Mentorship Chair in Innovative Clinical Trials for HIV Care. J.P.R. is the holder of the Louis Lowenstein Chair in Hematology and Oncology, McGill University. G.S. is supported by a Senior Salary Award from FRQS (#296306).

Conflicts of interest

B.L. has acted as a speaker and advisory board member for ViiV, Gilead, and Merck, and received research funding from ViiV, Merck, and Gilead. C.Cos. has received research funding from Merck, Gilead and Tilray Inc, speaker honorarium from Gilead and consultant fees from ViiV Healthcare and Moderna. She has received funding to attend conferences from Gilead and ViiV Healthcare, and cannabinoids from Tilray Inc. for use in a clinical trial. S.W. has served on advisory board, and spoken at CME event for Merck, Gilead, Viiv, and has received research funds from ViiV, Gilead and Merck. JC has received funding for investigator- initiated research from ViiV

Healthcare and remuneration for advisory work from Gilead Canada and ViiV Healthcare. M.C.M.M. has served on advisory boards and spoken at CME events for Merck, Gilead and Viiv, and has received research funds from Viiv. G.S. has acted as speaker for Merck, Gilead, Abbvie, NovoNordisk, Pfizer, served as an advisory board member for Pfizer, Merck, NovoNordisk, Gilead and Intercept and has received unrestricted research funding from Theratecnologies. F.C., S.S., D.K., L.R.B., W.E., E.E.M.M., C.P., K.M., N.P., N.K., A.D.P., J.P.R., M.B.K. have no conflict of interests.

Author statement

The principal investigator of the study is G.S. Site investigators of the study are M.B.K., C. Co., S.W., N.P., M.C.M.M. Other CTN co-applicants are S.S. (Methodologist), E.E.M.M. (Methodologist), K.M. (Community Representatives), C.P. (Community Representatives). G.S. conceived the study, led the proposal and protocol development. S.S. and E.E.M.M. provided methodological expertise and performed sample size calculations. F.C., D.K., L.R.B., W.E., B.L., J.C., N.K., C.Cos., J.P.R. and A.D.P. are involved in patient enrollment. F.C., S.S. and G.S. wrote the first draft of the manuscript. M.B.K., C. Co., S.W., E.E.M.M., N.P., M.C.M.M., D.K., L.R.B., W.E., J.C., B.L., N.K., C.Cos., J.P.R. and A.D.P. reviewed and edited the manuscript. All authors have read and agreed to the published version of the manuscript.

Table 1: Schedule of visits and procedures

Procedures:		Visit 1		Visit 2	Visit 3	Visit 4	Visit 5
		Screening	Baseline	Follow-Up (12 ± 3 months)	Follow-Up (24 ± 3 months)	Follow-Up (36 ± 3 months)	Follow-Up (48 ± 3 months)
Assessment of Eligibility		X					
Consent form		X	X	X	X	X	X
Fibroscan			X	X	X	X	X
Confirmation of Eligibility (includes Fibroscan result and AUDIT-C)			X				
Clinical Assessment	-Weight and Height to calculate BMI -Waist Circumference -Blood Pressure -Standard of Care Laboratory Tests		X	X	X	X	X
Biobanking	Plasma and serum sampling*		X				
Questionnaires	- Medical information questionnaire - Audit c - FFQ-SF - IPAQ-SF - CLDQ & SF 36 (PROS-HRQoL) - HATS questionnaire - Health resource utilization questionnaire		X	X	X	X	X
Report Laboratory Tests	- Liver profile (ALT, AST, GGT, alkaline phosphatase, total bilirubin, albumin, coagulation profile) - Complete blood count, biochemistry; fasting lipid profile, glucose and insulin fasting for at least 12 hours prior to bloodwork - Autoimmune markers (AMA, ANA, anti-LKM, ASMA, immunoglobulins); serum ferritin and transferrin saturation - Plasma HIV RNA; lymphocyte subsets (absolute and relative CD4, nadir CD4, CD8 T-cell counts)		X	X	X	X	X

	- HAV, HBV and HCV serology (if not documented within 1 year of study entry)		X				
In the Case of ACLD	6-monthly serum alpha-fetoprotein and ultrasound in patients who develop ACLD (Fibroscan >10 kPa)			X	X	X	X
	Outcome Measure Form (End stage Liver disease Form)			X	X	X	X
Chart Review	- Medical history: report hepatic and HIV-related diagnoses - Antiretroviral history; report past and current ART - Concomitant Medications; report ongoing medications	X	X	X	X	X	X

*Sub-study for 150 participants consent to banking plasma and serum samples for the McGill University Health Centre only

Abbreviations: ACLD, advanced chronic liver disease; ALT, alanine aminotransferase; AMA, antimitochondrial antibody; ANA, antinuclear antibody; anti-LKM; anti-liver/kidney microsomal antibodies; ART, antiretroviral therapy; ASMA, anti-smooth muscle antibody; AST, aspartate aminotransferase; AUDIT-C, Alcohol Use and Disorders Identification Test C; BMI, body mass index; CLDQ, Chronic Liver Disease Questionnaire; FFQ-SF, food frequency questionnaire – short form; GGT, gamma-glutamyl transferase; HATS, HIV adherence treatment scale; HAV, hepatitis A virus; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; HRQoL, health-related quality of life; IPAQ-SF, International physical activity questionnaire – short form; kPa, kilopascal; PROs, Patient reported outcomes; SF-36, Short Form-36

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Figure Legend

Figure 1. Sample size estimation.
Abbreviation: MASLD, metabolic dysfunction-associated steatotic liver disease.

Figure 2. Hypothetical pathogenesis of advanced chronic liver disease in HIV mono-infection.
Abbreviations: ACLD, advanced chronic liver disease; ART, antiretroviral therapy; HIV, human immunodeficiency virus; LIVEHIV, LIVER disease in HIV; MASLD, metabolic dysfunction-associated steatotic liver disease.

For peer review only

36/bmjopen-2023-076547 on 22 August 2023. Downloaded from <http://bmjopen.bmj.com/> on June 10, 2025 at Agence Bibliographique de l'Enseignement Supérieur (ABES).
Enseignement Supérieur (ABES).
All rights reserved. No reuse allowed without permission.
This article is published by copyright, including for uses related to text and data mining, AI training, and similar technologies.

References

- 1 Canada PHA of. Estimates of HIV incidence, prevalence and Canada's progress on meeting the 90-90-90 HIV targets, 2020. 2022.<https://www.canada.ca/en/public-health/services/publications/diseases-conditions/estimates-hiv-incidence-prevalence-canada-meeting-90-90-90-targets-2020.html> (accessed 15 May 2023).
- 2 Global HIV & AIDS statistics — Fact sheet. <https://www.unaids.org/en/resources/fact-sheet> (accessed 15 May 2023).
- 3 Palella FJ, Loveless MO, Holmberg SD. Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus Infection. *The New England Journal of Medicine* 1998.
- 4 Guaraldi G, Lonardo A, Maia L, *et al.* Metabolic concerns in aging HIV-infected persons: from serum lipid phenotype to fatty liver. *AIDS* 2017;**31**:S147–56. doi:10.1097/QAD.0000000000001483
- 5 Rosenthal E, Salmon-Céron D, Lewden C, *et al.* Liver-related deaths in HIV-infected patients between 1995 and 2005 in the French GERMIVIC Joint Study Group Network (Mortavic 2005 study in collaboration with the Mortalité 2005 survey, ANRS EN19). *HIV Med* 2009;**10**:282–9. doi:10.1111/j.1468-1293.2008.00686.x
- 6 Croxford S, Kitching A, Desai S, *et al.* Mortality and causes of death in people diagnosed with HIV in the era of highly active antiretroviral therapy compared with the general population: an analysis of a national observational cohort. *The Lancet Public Health* 2017;**2**:e35–46. doi:10.1016/S2468-2667(16)30020-2
- 7 de Franchis R. Expanding consensus in portal hypertension. *Journal of Hepatology* 2015;**63**:743–52. doi:10.1016/j.jhep.2015.05.022
- 8 Petta S, Sebastiani G, Viganò M, *et al.* Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease. *Clinical Gastroenterology and Hepatology* 2021;**19**:806-815.e5. doi:10.1016/j.cgh.2020.06.045
- 9 de Franchis R, Bosch J, Garcia-Tsao G, *et al.* Baveno VII – Renewing consensus in portal hypertension. *Journal of Hepatology* 2022;**76**:959–74. doi:10.1016/j.jhep.2021.12.022
- 10 Kaspar MB, Sterling RK. Mechanisms of liver disease in patients infected with HIV. *BMJ Open Gastroenterol* 2017;**4**:e000166. doi:10.1136/bmjgast-2017-000166
- 11 Paik JM, Henry L, Golabi P, *et al.* Presumed Nonalcoholic Fatty Liver Disease Among Medicare Beneficiaries With HIV, 2006–2016. *Open Forum Infect Dis* 2020;**7**:ofz509. doi:10.1093/ofid/ofz509

12 Rinella ME, Lazarus JV, Ratziu V, *et al.* A multi-society Delphi consensus statement on new fatty liver disease nomenclature. *Hepatology* Published Online First: 24 June 2023. doi:10.1097/HEP.0000000000000520

13 Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, *et al.* AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. *Hepatology* 2023;**Publish Ahead of Print**. doi:10.1097/HEP.0000000000000323

14 EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. *Journal of Hepatology* 2016;**64**:1388–402. doi:10.1016/j.jhep.2015.11.004

15 Younossi ZM, Golabi P, Paik JM, *et al.* The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. *Hepatology* 2023;**77**:1335–47. doi:10.1097/HEP.0000000000000004

16 Charlton MR, Burns JM, Pedersen RA, *et al.* Frequency and Outcomes of Liver Transplantation for Nonalcoholic Steatohepatitis in the United States. *Gastroenterology* 2011;**141**:1249–53. doi:10.1053/j.gastro.2011.06.061

17 Byrne CD, Targher G. NAFLD: a multisystem disease. *J Hepatol* 2015;**62**:S47–64. doi:10.1016/j.jhep.2014.12.012

18 Golabi P, Otgonsuren M, Cable R, *et al.* Non-alcoholic Fatty Liver Disease (NAFLD) is associated with impairment of Health Related Quality of Life (HRQOL). *Health and Quality of Life Outcomes* 2016;**14**:18. doi:10.1186/s12955-016-0420-z

19 Allen AM, Van Houten HK, Sangaralingham LR, *et al.* Healthcare Cost and Utilization in Nonalcoholic Fatty Liver Disease: Real-World Data from a Large US Claims Database. *Hepatology* 2018;**68**:2230–8. doi:10.1002/hep.30094

20 Cervo A, Shengir M, Patel K, *et al.* NASH in HIV. *Curr HIV/AIDS Rep* 2020;**17**:601–14. doi:10.1007/s11904-020-00531-0

21 Vuille-Lessard É, Lebouché B, Lennox L, *et al.* Nonalcoholic fatty liver disease diagnosed by transient elastography with controlled attenuation parameter in unselected HIV monoinfected patients. *AIDS* 2016;**30**:2635–43. doi:10.1097/QAD.0000000000001241

22 Pembroke T, Deschenes M, Lebouché B, *et al.* Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV co-infected patients and is associated with liver fibrosis. *Journal of Hepatology* 2017;**67**:801–8. doi:10.1016/j.jhep.2017.05.011

23 Kalligeros M, Vassilopoulos A, Shehadeh F, *et al.* Prevalence and Characteristics of Nonalcoholic Fatty Liver Disease and Fibrosis in People Living With HIV Monoinfection: A Systematic Review and Meta-analysis. *Clinical Gastroenterology and Hepatology* 2023;**S1542356523000289**. doi:10.1016/j.cgh.2023.01.001

- 24 Ryom L, De Miguel R, Cotter AG, *et al.* Major revision version 11.0 of the European AIDS Clinical Society Guidelines 2021. *HIV Med* 2022;**23**:849–58. doi:10.1111/hiv.13268
- 25 Sebastiani G, Milic J, Tsochatzis EA, *et al.* Letter to the editor: People living with HIV and NAFLD: A population left behind in the global effort for liver fibrosis screening? *Hepatology* Published Online First: 19 May 2023. doi:10.1097/HEP.0000000000000465
- 26 Guaraldi G, Maurice JB, Marzolini C, *et al.* New Drugs for NASH and HIV Infection: Great Expectations for a Great Need. *Hepatology* 2020;**71**:1831–44. doi:10.1002/hep.31177
- 27 Bush K, Kivlahan DR, McDonell MB, *et al.* The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. *Arch Intern Med* 1998;**158**:1789–95. doi:10.1001/archinte.158.16.1789
- 28 Loomba R, Lim JK, Patton H, *et al.* AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review. *Gastroenterology* 2020;**158**:1822–30. doi:10.1053/j.gastro.2019.12.053
- 29 Ajmera VH, Cachay ER, Ramers CB, *et al.* Optimal Threshold of Controlled Attenuation Parameter for Detection of HIV-Associated NAFLD With Magnetic Resonance Imaging as the Reference Standard. *Clin Infect Dis* 2020;**72**:2124–31. doi:10.1093/cid/ciaa429
- 30 Benmassaoud A, Nitulescu R, Pembroke T, *et al.* Liver-related Events in Human Immunodeficiency Virus–infected Persons With Occult Cirrhosis. *Clin Infect Dis* 2019;**69**:1422–30. doi:10.1093/cid/ciy1082
- 31 CTN 326: LIVEHIV Cohort Plus | Clinical Care and Management (CCM). CIHR Canadian HIV Trials Network. <https://www.hivnet.ubc.ca/study/ctn-326-livehiv-cohort-plus/> (accessed 6 Jun 2023).
- 32 Castera L. Noninvasive Methods to Assess Liver Disease in Patients With Hepatitis B or C. *Gastroenterology* 2012;**142**:1293–1302.e4. doi:10.1053/j.gastro.2012.02.017
- 33 Morse CG, McLaughlin M, Proschan M, *et al.* Transient elastography for the detection of hepatic fibrosis in HIV-monoinfected adults with elevated aminotransferases on antiretroviral therapy. *AIDS* 2015;**29**:2297–302. doi:10.1097/QAD.0000000000000841
- 34 Duarte M, Tien P, Ma Y, *et al.* Controlled attenuation parameter accurately detects liver steatosis in people with HIV. *AIDS* 2022;**36**:2147–52. doi:10.1097/QAD.0000000000003351
- 35 Mendeni M, Focà E, Gotti D, *et al.* Evaluation of liver fibrosis: concordance analysis between noninvasive scores (APRI and FIB-4) evolution and predictors in a cohort of HIV-infected patients without hepatitis C and B infection. *Clin Infect Dis* 2011;**52**:1164–73. doi:10.1093/cid/cir071

36 Cleghorn CL, Harrison RA, Ransley JK, *et al.* Can a dietary quality score derived from a short-form FFQ assess dietary quality in UK adult population surveys? *Public Health Nutrition* 2016;**19**:2915–23. doi:10.1017/S1368980016001099

37 Craig CL, Marshall AL, Sjöström M, *et al.* International physical activity questionnaire: 12-country reliability and validity. *Med Sci Sports Exerc* 2003;**35**:1381–95. doi:10.1249/01.MSS.0000078924.61453.FB

38 Fazeli PL, Marquine MJ, Dufour C, *et al.* Physical Activity is Associated with Better Neurocognitive and Everyday Functioning Among Older Adults with HIV Disease. *AIDS Behav* 2015;**19**:1470–7. doi:10.1007/s10461-015-1024-z

39 Younossi ZM, Stepanova M, Henry L, *et al.* A disease-specific quality of life instrument for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: CLDQ-NAFLD. *Liver Int* 2017;**37**:1209–18. doi:10.1111/liv.13391

40 Younossi ZM, Guyatt G, Kiwi M, *et al.* Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. *Gut* 1999;**45**:295–300. doi:10.1136/gut.45.2.295

41 Ware JE, Sherbourne CD. The MOS 36-Item Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection. *Medical Care* 1992;**30**:473–83.

42 Austin PC. The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments. *Stat Med* 2014;**33**:1242–58. doi:10.1002/sim.5984

43 Mertens BJ, Datta S, Brand R, *et al.* Causal effect estimation strategies in a longitudinal study with complex time-varying confounders: A tutorial. *Stat Methods Med Res* 2017;**26**:337–55. doi:10.1177/0962280214545529

44 Pavlou M, Ambler G, Seaman SR, *et al.* How to develop a more accurate risk prediction model when there are few events. *BMJ* 2015;**351**:h3868. doi:10.1136/bmj.h3868

45 Ware JH. The limitations of risk factors as prognostic tools. *N Engl J Med* 2006;**355**:2615–7. doi:10.1056/NEJMp068249

46 Pepe MS, Feng Z, Huang Y, *et al.* Integrating the predictiveness of a marker with its performance as a classifier. *Am J Epidemiol* 2008;**167**:362–8. doi:10.1093/aje/kwm305

47 Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. *Circulation* 2007;**115**:928–35. doi:10.1161/CIRCULATIONAHA.106.672402

48 Leening MJG, Vedder MM, Witteman JCM, *et al.* Net reclassification improvement: computation, interpretation, and controversies: a literature review and clinician’s guide. *Ann Intern Med* 2014;**160**:122–31. doi:10.7326/M13-1522

- 49 Hallager S, Brehm Christensen P, Ladelund S, *et al.* Mortality Rates in Patients With Chronic Hepatitis C and Cirrhosis Compared With the General Population: A Danish Cohort Study. *J Infect Dis* 2017;**215**:192–201. doi:10.1093/infdis/jiw527
- 50 van der Meer AJ, Veldt BJ, Feld JJ, *et al.* Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. *JAMA* 2012;**308**:2584–93. doi:10.1001/jama.2012.144878
- 51 Chen F, Xue Y, Tan MT, *et al.* Efficient statistical tests to compare Youden index: accounting for contingency correlation. *Stat Med* 2015;**34**:1560–76. doi:10.1002/sim.6432
- 52 Cai J, Sebastiani G. HIV, Elevated Transaminases, Fatty Liver: The Perfect Storm? *J Acquir Immune Defic Syndr* 2019;**81**:e23–5. doi:10.1097/QAI.0000000000001984
- 53 Iogna Prat L, Tsochatzis EA. Human Immunodeficiency Virus and Fatty Liver: The Perfect Storm or a Storm in a Teacup? *J Acquir Immune Defic Syndr* 2019;**81**:e25–6. doi:10.1097/QAI.0000000000001995
- 54 Benmassaoud A, Ghali P, Cox J, *et al.* Screening for nonalcoholic steatohepatitis by using cytokeratin 18 and transient elastography in HIV mono-infection. *PLoS One* 2018;**13**:e0191985. doi:10.1371/journal.pone.0191985
- 55 Brown TT. Antiretroviral Therapy and the Prevalence and Incidence of Diabetes Mellitus in the Multicenter AIDS Cohort Study. *Arch Intern Med* 2005;**165**:1179. doi:10.1001/archinte.165.10.1179
- 56 Sprinz E, Lazzaretti RK, Kuhmmer R, *et al.* Dyslipidemia in HIV-infected individuals. *The Brazilian Journal of Infectious Diseases* 2010;**14**:575–88. doi:10.1016/S1413-8670(10)70115-X
- 57 Kovari H, Weber R. Influence of antiretroviral therapy on liver disease: *Current Opinion in HIV and AIDS* 2011;**6**:272–7. doi:10.1097/COH.0b013e3283473405
- 58 Ingiliz P, Valantin M-A, Duvivier C, *et al.* Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy. *Hepatology* 2009;**49**:436–42. doi:10.1002/hep.22665
- 59 Merchante N, Pérez-Camacho I, Mira JA, *et al.* Prevalence and risk factors for abnormal liver stiffness in HIV-infected patients without viral hepatitis coinfection: role of didanosine. *Antivir Ther* 2010;**15**:753–63. doi:10.3851/IMP1612
- 60 Sulkowski MS, Mehta SH, Chaisson RE, *et al.* Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. *AIDS* 2004;**18**:2277–84. doi:10.1097/00002030-200411190-00008

61 Bischoff J, Gu W, Schwarze-Zander C, *et al.* Stratifying the risk of NAFLD in patients with HIV under combination antiretroviral therapy (cART). *EClinicalMedicine* 2021;**40**:101116. doi:10.1016/j.eclinm.2021.101116

62 Calza L, Colangeli V, Borderi M, *et al.* Improvement in liver steatosis after the switch from a ritonavir-boosted protease inhibitor to raltegravir in HIV-infected patients with non-alcoholic fatty liver disease. *Infect Dis (Lond)* 2019;**51**:593–601. doi:10.1080/23744235.2019.1629008

63 Macías J, Mancebo M, Merino D, *et al.* Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among Human Immunodeficiency Virus–Infected Patients With Nonalcoholic Fatty Liver Disease. *Clinical Infectious Diseases* 2017;**65**:1012–9. doi:10.1093/cid/cix467


64 Hanttu A, Vuoti S, Kivelä P, *et al.* Liver Fat, Adipose Tissue, and Body Composition Changes After Switching from a Protease Inhibitor or Efavirenz to Raltegravir. *AIDS Patient Care STDS* 2021;**35**:335–41. doi:10.1089/apc.2021.0106


65 Maurice JB, Goldin R, Hall A, *et al.* Increased Body Mass Index and Type 2 Diabetes Are the Main Predictors of Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in Liver Biopsies of Patients With Human Immunodeficiency Virus Monoinfection. *Clin Infect Dis* 2021;**73**:e2184–93. doi:10.1093/cid/ciaa1302

66 Petroff D, Blank V, Newsome PN, *et al.* Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis. *The Lancet Gastroenterology & Hepatology* 2021;**6**:185–98. doi:10.1016/S2468-1253(20)30357-5

67 Friedrich-Rust M, Ong M-F, Martens S, *et al.* Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. *Gastroenterology* 2008;**134**:960–74. doi:10.1053/j.gastro.2008.01.034

68 Lemoine M, Assoumou L, De Wit S, *et al.* Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study. *J Acquir Immune Defic Syndr* 2019;**80**:e86–94. doi:10.1097/QAI.0000000000001936





STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Reported on page
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Page 1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Page 3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	Page 5
Objectives	3	State specific objectives, including any prespecified hypotheses	Page 7
Methods			
Study design	4	Present key elements of study design early in the paper	Page 8
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Page 8
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	Page 8
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Page 9
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Page 9
Bias	9	Describe any efforts to address potential sources of bias	Page 14 and 19
Study size	10	Explain how the study size was arrived at	Page 10
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Page 14
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	Page 14
		(b) Describe any methods used to examine subgroups and interactions	Page 14
		(c) Explain how missing data were addressed	NA**
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	NA**
		(e) Describe any sensitivity analyses	

Results			NA**
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	
Discussion			NA**
Key results	18	Summarise key results with reference to study objectives	
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	
Generalisability	21	Discuss the generalisability (external validity) of the study results	
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Page 21

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

**** Note of the authors:** Since our manuscript is a protocol study of a study still recruiting participant, some of the items (i.e. results and discussion) were Not Applicable (NA)